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Thesis	  Abstract	  
Background: This thesis presents novel research relative to medical device 
enhancements used to improve the treatment of atrial fibrillation. Specifically, atrial 
septal punctures, mitral isthmus linear ablations, and the recording of monophasic action 
potentials all retain important roles in overall procedure success for the clinical 
intervention of atrial fibrillation using an ablative therapy. The fundamental premise for 
these medical device innovations is to improve procedural safety and therapeutic 
outcomes.  The continued development of clinical tools and approaches for such 
procedures will require medical device innovators to understand variability in underlying 
patient anatomies. I believe this thesis provides critical insights on underling anatomic 
features and engineering parameters that could dictate how such innovations could be 
advanced. 
 
Approach:  My thesis is composed of a series of studies that focus on: 1) characterizing 
device efficacy for transseptal puncture; 2) improvements in device utilization for the 
creation of linear lesions in the region of the mitral isthmus; 3) detailed descriptions of 
proposed ablation procedural approaches that provide critical insights as to potential 
effect on adjacent anatomies; and 4) applications of innovative monitoring tools to collect 
monophasic action potentials and associated contact forces, thereby enhancing detection 
of arrnythmogenic myocardium therapeutic targets and resultant lesion formations.  
 
Specifically, fossa ovalis anatomy was evaluated using swine and human specimens;  
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direct assessments of fossa ovalis biomechanical properties were performed and means to 
perform transseptal puncture procedures were identified. To accomplish this, I developed 
novel methodologies for assessing both puncture and tear. I also sought to determine the 
relative utility of employing the swine fossa ovalis as a predictive indicator for human 
tissue responses. Further, novel approaches were evaluated against a set of clinically 
available puncture devices, e.g., those that use either mechanical or radiofrequency 
puncture approaches. The specimens were also subjected to different sized sheath devices 
as another means to better understand the relative properties of the given species’ septal 
anatomy for eliciting punctures and/or tearing.  
 
In another set of studies described within my thesis, using human cardiac tissue, a new 
procedural technique (with currently available clinical devices)  was developed as a 
means to potentially augment a physician’s ability to generate effective linear lesions in 
the regional anatomy of the mitral isthmus; it was possible to assess such approaches 
within human cardiac specimens as well. Additionally, magnetic resonance imaging was 
employed on multiple perfusion-fixed human specimens to provide detailed associated 
anatomies of the mitral isthmus and coronary sinus, as a means to provide important 
insights to both clinicians and medical device designers regarding improved procedural 
approaches taking into consideration collateral structures as well as next generation 
ablative devices.  
 
Finally, I have described experimental approaches to record monophasic action potential  
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contact force data using custom constructed catheters. It was shown that this approach 
allowed me to evaluate how varied cardiac anatomies may affect a user’s ability to collect 
reproducible monophasic action potentials as a means to obtain important clinical 
information during a clinical ablative procedure. 
   
Summary: In this thesis, I have shown that the fossa ovalis anatomy of the swine can 
serve as a useful surrogate, within the range of responses that one may encounter 
clinically in humans. Furthermore, I have also shown what the impact may be of utilizing 
various methods for performing transseptal puncture procedures, as well as, the relative 
impact of employing a range of delivery catheter sizes. I consider that the results of the 
novel studies I describe here will contribute to the future of individuals working in this 
field, to develop safe transseptal devices that will also reduce damage of associated 
anatomies. Further, I describe unique ablative procedural techniques as well as various 
device improvements which could specifically improve therapeutic outcomes for creating 
linear mitral isthmus ablation lines. Finally, I describe the required contact forces and 
other recording parameters that would be needed to appropriately collect monophasic 
action potentials in various locations throughout cardiac anatomies (endocardial and 
epicardial). This information should provide novel clinical insights that could then be 
used to design future tools and/or techniques that may even change how a given ablative 
procedure is conducted.  
 
Therefore, the overall described experimental outcomes within my thesis will increase  
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one’s understanding of associated cardiac anatomy relative to therapeutic approaches for  
treating atrial fibrillation and the procedures to do so, and also inspire novel clinical 
approaches and/or the next generation of catheter-based detection of arrhythmogenic 
tissue and lesion generation. 
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Figure 1.1  In this image of the RA, all of the 5 locations shown on the FO are 
transseptal puncture possibilities.  The green arrow depicts the path of device 
delivery to the FO. CS Os – coronary sinus ostium, ER – eustachian ridge, FO – 
fossa ovalis, IVC – inferior vena cava, RA – right atrium. .  . . . . . . . . . . . . . . . . .  
 
 
 
 
7 
Figure 1.2  In the diagram on the left (A), the green arrows depict the IVC 
approach to transseptal punctures.  The image on the top right (B) shows the FO 
and ER.  The image on the bottom right (C) shows a patent foramen ovale in the 
FO, with the ER adjacent to the FO. ER – eustachian ridge, FO – fossa ovalis, 
IVC – inferior vena cava .   
 
 
 
 
8 
Figure 1.3  This image shows the catheter dilator and sheath in the RA.  The red 
rectangle contains pectinated muscles that border the ER.  ER – eustachian 
ridge, RA – right atrium  . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
9 
Figure 1.4  The image on the left (A) shows deformation of the FO at the point 
of needle puncture in the LA. The image in the center (B) shows a transseptal 
puncture at the time of dilator insertion, with deformation of the FO (red oval) 
and a tight fit between the dilator and the FO.  The image on the right (C) shows 
3 areas: 1, the septal ridge around the FO; 2, the thin and highly compliant 
nature of the FO; and 3, the ER. ER – eustachian ridge, FO – fossa ovalis  . . . . .  
 
 
 
 
 
 
10 
Figure 1.5  The image on the left (A) shows the view from the LA of the FO at 
the point of needle puncture.  The image on the right (B) shows the 
simultaneous view from the RA at the point of needle puncture. FO – fossa 
ovalis, LA – left atrium, RA – right atrium . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
11 
Figure 1.6  In the diagram on the left (A), the green arrows depict the path of 
device delivery to the PV originating from the FO.  The image on the right (B) 
shows LA sheath placement after a transseptal puncture, with a guidewire 
introduced into the RSPV. FO – fossa ovalis, LA – left atrium. PV – pulmonary 
vein  
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Figure 1.7  Example of potential complication as a result of catheter navigation  
performed in a swine showing FO tearing due to excessive deflection force from 
a delivery sheath attempting to navigate into a PV. . . . . . . . . . . . . . . . . . . . . .   
 
 
 
12 
Figure 1.8  In the diagram on the left (A), the green arrows depict the device 
approach originating from the IVC into the CS ostium.  The image on the right 
(B) shows the regional anatomy in the area of the CS bordered by the thebesian 
valve, including the IVC catheter introduction point. CS – coronary sinus, IVC - 
inferior vena cava. . . . . . .  
 
 
 
 
14 
Figure 1.9  In this image, the green arrow depicts the device approach 
originating from the IVC.  IVC = inferior vena cava . . . . . . . . . . . . . . . . . . . . . . .  
 
 
15 
Figure 1.10  The diagram on the left (A) shows the approach to the RAA 
through the IVC.  The image on the top right (B) shows the large size of the 
RAA and pectinated muscles.  The image on the bottom right (C) shows the 
pectinated muscles and thin tissue. . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
16 
Figure 1.11  In the diagram on the left (A), the green arrows depict the 
directions of device introduction originating from the FO into the LA pulmonary 
anatomy.  The image on the top right (B) shows the left PV ostium.  The image 
on the bottom right (C) shows the right PV ostium. FO – fossa ovalis, LA – left 
atrium, PV pulmonary vein 
 
 
 
 
18 
Figure 1.12  The image on the left (A) shows the catheter sheath and the use of a 
guidewire for placement into the RSPV.  The image in the center (B) shows the 
introduction of the catheter tip at the PV ostium.  The image on the right (C) 
shows the retraction of the catheter sheath to the FO and the introduction of a 
balloon catheter.FO – fossa ovalis, RSPV – right superior pulmonary vein, PV – 
pulmonary vein . . . . . . . . .  
 
 
 
 
 
20 
Figure 1.13  The image on the left (A) shows the catheter sheath and the use of a 
guidewire for placement into the LSPV.  The image in the center (B) shows the 
placement of the guidewire into the PV ostium. The image on the right (C) 
shows the introduction of the balloon catheter across the LA.  LA – left atrium, 
LSPV – left superior pulmonary vein, PV – pulmonary vein . .. . . . . . . . . . . . . . .  
 
 
 
 
 
21 
Figure 1.14  In this image of a balloon-based LA RSPV occlusion, the sheath is  
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retracted to accommodate the ablation catheter (red circle).  The catheter  
orientation (green arrow 1) is not aligned with the PV ostium orientation (green 
arrow 2). LA – left atrium, PV – pulmonary vein , RSPV – right superior 
pulmonary vein. . . . . . . . . . . . . . .  
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Figure 1.15 In the diagram on the left (A), the green arrow indicates the 
approach to the LAA from the FO.  The image on the top right (B) shows the 
position of the LAA relative to the MVA and the presence of pectinated muscle. 
The image on the bottom right (C) shows the position of the LAA relative to 
both the MV and the LSPV.FO – fossa ovalis, LAA – left atrial appendage, 
LSPV – left superior pulmonary vein, MV – mitral valve . . . . . . . . . . . . . . . . . . .  
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Figure 1.16  This image shows the catheter shaft circulating around the LAA 
ostium; the red circle depicts the ridge between the LAA and LSPV. LAA – left 
atrial appendage, LSPV – left superior pulmonary vein  . . . . . . . . . . . . . . . . . . . .  
 
 
 
24 
Figure 1.17  The diagram on the left (A) shows the MV in the LA.  The image 
(B) notes various structures, including the MVA, which serves as the starting 
point for creating a linear lesion in the MI.  LA – left atrium, MV – mitral valve, 
MVA - mitral valve annulus. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
25 
Figure 1.18  The image on the left (A) shows MI lesion creation originating at 
the MVA.  The image on the right (B) shows creation of a roofline linear lesion. 
MI – mitral isthmus, MVA – mitral valve annulus. .. . . . . . . . . . . . . . . . . . . . . . .  
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Figure 2.1  Radial adhering suction device for stabilization of the atrial septum 
for tissue puncturing. (A) Force testing machine with transseptal device attached 
and puncturing the atrial septum. (B) Close-up view of the atrial septum and 
stabilization device employed for puncturing. . . .  . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
37 
Figure 2.2 Schematic of transseptal devices used for testing. The dilator was 
seated into the sheath and attached at the proximal end via adhesive. The center 
lumen was kept clear for a needle to be placed through it and protrude from the 
distal tip. . . . . . . . . . . . .   
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Figure 2.3 Location of the fossa ovalis (FO) in relation to other anatomy within 
the right atrium (RA): the inferior vena cava (IVC), and the coronary sinus 
ostium (CS Os). The numbers indicate various puncture locations: (1) center, (2) 
inferior, (3) posterior, (4) superior, and (5) anterior. . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 2.4 Characteristic force verses distance graph during fossa ovalis 
puncturing. Note the distinctive peaks during each transition of the dilator and 
sheath; upon reaching a new layer, the force increases due to the need for fossa 
ovalis expansions. . .  
 
 
 
42 
Figure 2.5 Schematic representation of the fossa ripping test setup. The 
muscular tissue adjacent to the septum primum (posterior rim of the fossa ovalis 
for posterior pulls and superior rim for inferior pulls) was cut off to allow the 
sheath to fully disengage from the atrial septum without consequence from the 
muscular portion of the atrium surrounding the floor of the fossa ovalis (A). The 
fossa ovalis was ripped by a catheter which was inserted through the floor of the 
fossa ovalis in the mechanical force tester (B). An example of the resultant force 
versus extension plot is shown in (C). . . . . . . . . 
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Figure 2.6 Example of prepared dog-bone shaped sample used for testing (A) 
and with 2-0 silk suture attached while mounted in the testing pull tester (B). . . .  
 
44 
Figure 2.7: Forces required to tent the fossa ovalis by 8mm. Experiments were 
performed on excised human (n=8) and swine (n=40) hearts. (*=p<0.01, 
**=p<0.001) 
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Figure 2.8 Average peak forces required to pass various portions of 10F sheath 
through the septum primum in isolated septa of human and swine hearts. 
Significant differences were found between these two species when comparing 
the tip of the dilator, dilation, and sheath forces (*=p<0.01, **=p<0.001) . . . . . .  
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Figure 2.9 Histogram of recorded peak forces required to traverse the septum 
with various portions of a 10F sheath. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 2.10 Relative forces required to traverse the atrial septum with various 
portions of a transseptal sheath of difference sizes. (Ŧ=p<0.001 based on 
ANOVA) . . . . . . . . . .  
 
 
50 
Figure 2.11 Minimum and maximum diameters of induced iatrogenic atrial 
septal defects, following transseptal punctures employing various sized 
catheters. . . . . . . . . . .  
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Figure 2.12 Relative forces required to transition a catheter system through a 
septum from one portion of the transseptal puncture sheath to another. An 
increase in the cross-sectional area of the relative portions of the catheter 
required more force to pass the catheter through a given septum. . . . . . . . . . . . . .  
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Figure 2.13 Catheter size versus average tearing force. Tearing forces of the 
fossa ovalis increased with the usage of a larger diameter sheath, but did not 
significantly differ between the 4F and 12F sheaths (p>0.05). Error bars depict 
mean±SE. *p-value<0.001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
55 
Figure 3.1 The photo on the left (A) shows a swine heart’s torn fossa ovalis 
(FO), with a sheath through the opening made by a transseptal puncture, as 
viewed from the left atrium.  The photo on the right (B) shows a human FO 
puncture, as viewed from the left atrium. . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
67 
Figure 3.2 The photo on the left (A) shows our study’s 3 transseptal puncture 
devices, from top to bottom (scale bar = 1 cm): a 5-French RF electrode with the 
tip of a transseptal needle (ETN), a radiofrequency transseptal needle (RFTN), 
and a conventional curved transseptal needle (TN). The diagram on the right (B) 
depicts the components of the 3 devices (purple = sheath, green = dilator). . . . . .  
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Figure 3.3 The diagram on the left (A) depicts the setup for transseptal 
punctures, with the device positioned to be inserted through the fossa ovalis 
(FO) mounted on a plate; all 3 components—sheath (S), dilator (D), and needle 
(N)—were oriented perpendicular to the specimen. The photo on the right (B) 
shows septal tissue prepared for puncture (red oval = the FO). . . . . . . . . . . . . . . .  
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Figure 3.4 The diagram on the left (A) depicts force data (in grams) for all 
tearing and puncturing, by needle type: transseptal needle (TN), radiofrequency 
TN (RFTN), or 5-French RF electrode with the tip of a TN (ETN).  The diagram 
on the right (B) depicts force data (in grams) for all tearing and puncturing, by 
sheath size: 12-, 16-, 18-, or 23-French. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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Figure 3.5 The diagram on the left (A) shows, for all specimens, the mean 
puncture force and standard deviation (SD) (in grams) for the needle, dilator, 
and sheath by sheath size. The diagram on the top right (B) shows, for all 
specimens, the mean puncture force and SD (in grams) by needle type: 
transseptal needle (TN), radiofrequency TN (RFTN), or 5-French RF electrode 
with the tip of a TN (ETN).  The diagram on the bottom right (C) shows the 
relationship between dilator and sheath puncture forces with an overall R2 of 
0.29. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .      
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Figure 3.6 This diagram shows the mean puncture force and standard deviation 
(in grams) by needle type and sheath size. * P ≤ 0.05 . . . . . . . . . . . . . . . . . . . . .  
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Figure 3.7 The diagram on the left (A) depicts the puncture force (in grams), 
with data normalized against the transseptal needle (TN) and 12-French size, by 
needle type: TN, radiofrequency TN (RFTN), or 5-French RF electrode with the 
tip of a TN (ETN).  The diagram on the right (B) depicts the transseptal crossing 
force (in grams) by sheath size: 12-, 16-, 18-, or 23-French. . . . . . . . . . . . . . . . . . 
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Figure 3.8 This diagram depicts the peak septal tearing forces by sheath size: 12-
, 16-, 18-, or 23-French. The only significant difference occurred when using the 
23-French sheath, as compared with the other 3 sizes. *P < 0.001 . . . . . . . . . .  
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Figure 3.9 This 3-part diagram depicts the relationship between FO thickness (in 
mm) and puncture force (in grams) using (A) the transseptal needle (TN); (B) 
the 5-French radiofrequency electrode with the tip of a TN (ETN); and (C) the 
RFTN. . . . . . . . . . . . .  
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Figure 4.1  Mitral isthmus linear lesion was created in a reanimated human 
heart: (A) shown in the initiation of linear lesion with support from transseptal 
sheath and secondary diagnostic catheter; (B) the ablation catheter –1– is pulled 
along MI with twisting of diagnostic catheter -2- towards FO and retraction of 
transseptal sheath – 3 – from LA; (C) shown is an increased deflection of 
ablation catheter – 4 – and increased twisting of diagnostic catheter – 5.  The 
uses of both the transseptal sheath and a support catheter was advantageous to 
maintain contact on the MI. LA – left atrium, MI – mitral isthmus, MV – Mitral 
valve, PV – pulmonary vein . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 4.2  Shown are several views of sectioned and TTC stained left atrial 
samples: (A) the ablated atrial tissue appear as blanched; (B) shown is the PV 
inverted and the MI line is circled; and (C) cross-section view of linear mitral 
isthmus lesion, depicting transmurality. 
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Figure 4.3  Shown is the movement of the catheter using a traditional approach 
A) catheter tip movement (green arrow) over the ridge (blue dash) B) catheter 
tip drag (green arrow) starting a MI in the direction of the ridge (blue dash).  . . 
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Figure 5.1  Schematic diagram of the cross-section along the mitral isthmus (MI) from 
the mitral valve annulus to the left inferior pulmonary vein (LIPV). The blue vessel 
represents the coronary sinus (CS); the red vessel, the left circumflex artery. 1 indicates 
the long and thick MI; 2, the recess/pouch/crevice; 3, the muscular sleeve around the 
CS; 4, convective cooling by blood flow in the CS and the artery; 5, the 0° position of 
the CS circumference. . . . . . . . . . . . .  
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Figure 5.2 Anatomic reconstruction of the left atrium (LA), coronary sinus (CS),  
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and left inferior pulmonary vein (LIPV). The yellow mitral isthmus (MI) plane 
line intersects the CS center line as measured in the reconstructed 3-dimensional 
model.  The light blue line depicts the CS center line. . .. . . . . . . . . . . . . . . . . . . .  
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Figure 5.3 A magnetic resonance imaging (MRI) image (left) and a photograph 
of the same human heart specimen (right). The left atrium (LA) endocardial 
space is labeled (left atrium). The specimen section includes the coronary sinus 
(CS); immediately inferior to it is a deposit of fat that is visible on both the MRI 
image and the photograph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
 
109 
Figure 5.4  Analysis of the coronary sinus (CS) at the mitral isthmus (MI). The 
0º to 180º line is parallel to the mitral annulus. Using the CS center line, we 
created degree positions around the CS (0º, 90º, and 180º), in order to measure 
distances to the endocardial MI.  The left atrium (LA) and left ventricle (LV) are 
labeled for reference. 
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Figure 5.5 Presence of fat and distance to mitral isthmus (MI) at the position of 
the coronary sinus (CS) at the MI plane, in degrees around the CS: red, atrial 
fibrillation (AF) group; blue, non-AF group.  (A) Distance around the CS at the 
MI plane to the left atrium (LA) space, in mm.   (B) Bar chart comparing the 
percentage of hearts where fat was present, next to different positions on the CS.  
The shortest label (–) compares the 0° AF position with the shortest (15°) non-
AF position. . . . . . . . . . . . . . . 
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Figure 6.1  Epicardial sites for CF/MAP signals collection. RVOT = right 
ventricular outflow tract, RV = right ventricle, LV = left ventricle RAA = right 
atrial appendage, CS = coronary sinus, RA = right atrium . .. . . . . . . . . . . . . . . . .  
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Figure 6.2  (A) Design of the tip of the MAP catheter (4) with 4 distal electrodes 
(2) and 2 – 2 mm band electrodes (5) that are mounted on the shaft of the 
catheter.  The tip electrodes are isolated from each other using a polymer (1, 3); 
the catheter is able to collect both unipolar and bipolar signals. (B) Illustrates the 
catheter tip as it engages the tissue surface.  The electrodes and fiber Bragg 
grating strain sensor (orange tube) come in contact with the tissue at the same 
time.  Contact is denoted by deformation of the fiber grating in the right panel of 
(B).  This deformation is translated into grams of CF. CF = contact force, MAP 
= monophasic action potential . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 6.3  MAP depolarization and repolarization. During phase 0 
(depolarization), sodium enters the cell; during phase 2, calcium enters the cell 
and contraction starts; during phase 3 (repolarization), potassium exits the cell. 
MAP = monophasic action potential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 6.4  (A) Signals that served to define AT, APD, and RT.  (B) A single 
MAP (purple) and ECG (black) signal captured on the RV epicardium.  (C) 
Catheter orientation, direction of motion, and orientation for epicardial 
measurements. APD = action potential duration, AT = sum of activation time, 
ECG = electrocardiography, MAP = monophasic action potential, RT = 
repolarization time, RV = right ventricle 
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Figure 6.5  (A) The catheter contained within the delivery sheath/fixture was 
oriented to be perpendicular to the epicardial surface of the right ventricle (RV).  
(B) The catheter’s electrode tip and fiber Bragg grating were near the 
endocardial surface in the right atrium on the Visible Heart® apparatus. . . . . . . .    
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Figure 6.6 Catheter tissue CF (including the mean and SD) is depicted at all 
endocardial and epicardial mapping points.  Color bars indicate 100% of 
measurements by anatomic location; the percentage breakdowns, bands of CF 
(grams); gray bars, the mean and SD at each anatomic point.  At the far right, 
the number of points by anatomic location is indicated in either an epicardial 
(Epi) or endocardial (Endo) grouping. CF = contact force, RVOT = right 
ventricular outflow tract, RV = right ventricle, LV = left ventricle RAA = right 
atrial appendage, CS = coronary sinus, RA = right atrium, gm = grams .  . . . . . .  
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Figure 6.7  (A) We collected all of these points, in 7 anatomic locations.  (B) 
We organized the 7 anatomic locations by CF color bands. (C) The blue dot is 
the mean CF, the grey dots are each observation.  CF = contact force, RV = right 
ventricle, LV = left ventricle RA = right atrium, gm = grams . . . . . . . . . . . . . . . .  
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Figure 6.8 Each line represents an individual swine heart (n = 7).  The “first 4” 
point indicates the mean contact force (CF) required to generate 4 consecutive 
monophasic action potentials (MAPs) across all epicardial anatomic points;  the 
“all on” point, the mean CF when the catheter tip is fully engaged in the tissue; 
and the “last 4” point, the last 4 consecutive MAPs. . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
 
 
137 
Figure 6.9  (A) a total of 9 anatomic locations showing the distribution of CF at 
each location.  (B)  9 anatomic locations by CF color bands. (C) The mean is 
shown by blue dot,  all observations are grey dots within 3 bands for all points.  
CF = contact force, RVOT = right ventricular outflow tract, RV = right 
ventricle, LV = left ventricle RAA = right atrial appendage, CS = coronary 
sinus, RA = right atrium. gm = grams . . . . . . . .  
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Figure 6.10  CF differences at each epicardial point collection location.  (A) CF 
is shown at the right ventricular outflow tract (RVOT), right ventricular apex  
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(RV apex), and the left ventricular apex (LV Apex) 3 epicardial points.  (B) CF 
is shown at 4 epicardial septum locations of the RV septum. RVOT = right 
ventricular outflow tract, RV = right ventricle . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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Figure 6.11  (A) 9 endocardial locations by whether CF was significantly (blue) 
or nonsignificantly (purple) different from the normalized epicardial reference 
(yellow).  (B) 7 epicardial locations by whether CF was significantly (blue) or 
nonsignificantly (purple) different from the normalized epicardial reference 
(yellow) CF = contact force, RVOT = right ventricular outflow tract, RV = right 
ventricle, LV = left ventricle RAA = right atrial appendage, CS = coronary 
sinus, RA = right atrium . . . . . . . . . . . . . . . . . .  
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Figure 6.12  The signal on the left had sufficient CF (contact force). The change 
in the signal as the catheter was removed is depicted on the right: that CF was 
insufficient to generate monophasic action potentials (MAPs). . .. . . . . . . . . . . . .  
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Figure 6.13 Changing the catheter tip orientation and position changed the 
contact force (CF) at the same anatomic epicardial location. . . . . . . . . . . . . . . . .   
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Figure 7.1  Shown is a depiction of the employed MAP catheter applied to the 
cardiac tissue: with a TAP moving past the type of the catheter with an 
amplitude of 30 mV.  The simultaneous deflections of the fiber Bragg grating 
provided the simultaneous force information.  TAP - transmembrane action 
potential, MAP – monophasic action potential .  . . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 7.2  Imaged of ablations performed on the reanimated swine heart 
specimens: (A) epicardial linear lesion on the RV with upper oval as external 
pacing site and lower oval contains tip of MAP catheter, and (B) LA endocardial 
image showing mitral isthmus linear lesion creation moving towards mitral 
valve annulus (green arrow).  LV – left ventricle, and MV mitral valve  RAA – 
right atrial appendage, RV – right ventricle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 7.3  Elicited epicardial lesion patterns: (A) location of the linear lesion 
pattern on RV; (B) CF applied in different anatomic locations on or adjacent to 
the lesion pattern.  CF is indicted for each location with red indicating no MAPs 
were detected and the green indicates that MAPs were elicited.  CF – contact 
force, MAP – monophasic action potential, RV right ventricle. . . . . . . . . . . . . .  
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Figure 7.4  Provided here are the noted CFs for the placements of our  
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assessment catheter at 9 anatomical locations on the endocardium of the LA in 
the region of the MI.  Red bars indicates that no MAP was elicited and green 
indicates that a MAP recordings were obtained.  CFs in grams are listed for each 
of 9 locations on the lesion.  CF – contact force, LA – left atrium, MI – mitral 
isthmus. . . . . . . . . . . . . . . . . . . . . . . . .  
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Preface	  
The inspiration for this study arose as a result of known limitations that originate with the 
devices that are used in the treatment of atrial fibrillation.  The current procedure uses a 
number of different devices that perform unique steps in the procedure.  Each of the 
devices have inherit limitations that originate from the device design and these limitations 
are confounded by the anatomy in which they are intended to operate.  Variations in the 
anatomy pose challenges in that a given device design may not be appropriate for all 
instances of use.   
The use of direct visualization in a functional heart uncovers where the limitations may 
exist in the device tissue interface that are not easily visible under current procedural 
imaging modalities.  
This chapter is designed to review the current procedure and discover opportunities 
where limitations between device design and anatomy exist such that further study may 
be conducted to suggest areas of improvement to either the procedure or the device 
design.  The material in this chapter has been submitted to World Journal of Cardiology. 
For this study, I was responsible for study design, image analysis, and publication 
creation. Paul Iaizzo provided editing.   
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Summary	  
 
Endocardial access to the left atrium is commonly achieved to treat patients with atrial 
fibrillation, using different device delivery systems for cardiac ablation.  But the large 
variation in human anatomy presses the limits of existing medical devices.  In our unique 
study, we used direct visualization with Visible Heart® of the device-tissue interface in 
fresh reanimated human hearts.  Our goal was to better understand any opportunities to 
improve therapeutic approaches.  
The visual images we obtained in our study (and feature in this article) allow a more 
intimate grasp of the key steps required in various ablation procedures and of any 
limitations of current device designs.  These images show the potential risks of 
conducting transseptal punctures and the difficulties of placing catheter tips in certain 
scenarios (e.g., when creating circumferential lesions, and potential problems that could 
occur in attempting to place catheter tips on such anatomies like the mitral isthmus).  In 
our analysis of these images, we focused on where enhancements are needed to refine 
device functionality.   
 
Keywords: Atrial fibrillation, cryogenic catheter ablation, radiofrequency ablation, 
transseptal punctures 
 
Abbreviation List: AF = atrial fibrillation, CS = coronary sinus, ER = Eustachian ridge, 
FO = fossa ovalis, IVC = inferior vena cava, LA = left atrium, LAA = left atrial  
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appendage, MI = mitral isthmus, MV = mitral valve, MVA = mitral valve annulus, PV =  
pulmonary vein, RA = right atrium, RAA = right atrial appendage, RIPV = right inferior 
pulmonary vein, RSPV = right superior pulmonary vein  
Introduction	  
For many years, ablation (either radiofrequency or cryogenic) has been used to treat 
patients with atrial fibrillation (AF). [1-3] But variations in cardiac anatomy have 
consistently influenced therapeutic success. [4-8] Different medical device designs have 
been developed for creating effective lesions in such varied anatomic structures. [9-12]   
However, in order to apply therapies for left atrium (LA) targets, navigation is first 
required into the right atrium (RA) and then across the septum.   
Reaching the anatomic locations within the left heart was initially made feasible by Cox’s 
maze procedure.[13-16]  In such a procedure, each step requires an intimate understanding 
of the endocardial anatomy.[17] Importantly, the inappropriate placement of devices in any 
ablation procedure can result in significant unintended consequences, including the 
creation of  ineffective lesions (no transmurality), the need for subsequent ablation 
procedures, or cardiac tamponade during transseptal punctures.[18-20] 
In an effort to reduce the incidence of such unintended consequences, ablation is 
commonly performed with the assistance of imaging tools such as fluoroscopy or 
echocardiography.  Imaging tools not only help eliminate unintended consequences, such 
as perforation, but also help ensure occlusion of pulmonary veins (PVs).  In addition, the  
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use of fluoroscopy, angiography, and noncontact mapping has improved the quality of the 
images.[21]  However, no imaging method allows us to directly visualize the device-tissue 
interface or to take into consideration the impact of accuracy on heart rhythm.[21,22]    
 
In our unique study, we used Visible Heart® methods to directly visualize the device-
tissue interface in fresh human hearts reanimated in a clear Krebs-Henseleit buffer (Sigma-
Aldrich Corporation, St. Louis, MO), as previously described.[22, 23]   Our goal was to better 
understand any opportunities to improve therapeutic approaches during the key steps of 
various ablations procedures.  The visual images we obtained in our study (and feature in 
this article) allow a more intimate grasp of the steps required and of any limitations of 
current device designs.   
 
In particular, the images reveal the interaction of ablation technology with human tissue, 
providing a sense of the spatial relationship between the device and anatomic structures.  
In our analysis of these images, we focused on where enhancements are needed to refine 
device functionality. For purposes of our analysis, we separated the key steps of ablation 
procedures into 3 distinct image sets, distinguished by the device used and the anatomy: 
(1) navigating the RA; (2) conducting transseptal punctures from the RA to the LA; and 
(3) creating lesions and reaching the key anatomic locations in the LA with different type 
of ablation devices.  Delineating the limitations of current devices and pinpointing the 
major anatomic challenges should prove to be of great importance for both practicing  
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physicians and medical device designers.[23]    
Navigating	  the	  RA	  	  
Success in navigating the RA has been limited, given the challenging anatomy of key RA 
structures combined with the limitations of current device design.  Endocardial cardiac 
ablations of the atria commonly originate via access from the inferior vena cava (IVC).  
An introducer, at the groin, is inserted into the femoral vein and then advanced into the 
RA.  The IVC serves as a low-pressure return path of deoxygenated blood to the RA.  
Thus, the IVC is a suitable starting point for endocardial procedures because it eliminates 
risks associated with device introduction.  Key ablation procedure structures in the RA 
include the fossa ovalis (FO), coronary sinus (CS), and right atrial appendage (RAA).   
Fossa	  Ovalis	  
The FO serves as the access point for ablation of the LA.  As devices enter the RA, the 
Eustachian valve of the IVC forms a bridge between the IVC and the Eustachian ridge 
(ER)    (Figure 1.1). 
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Figure 1.1:  In this image of the RA, all of the 5 locations shown on the FO are 
transseptal puncture possibilities.  The green arrow depicts the path of device delivery to 
the FO. CS Os – coronary sinus ostium, ER – eustachian ridge, FO – fossa ovalis, IVC – 
inferior vena cava, RA – right atrium.  
The FO is also a structure that causes devices to bind or become lodged; device tips can 
catch on the compliant membrane of the valve. [24, 25, 26]  Because the FO and the IVC are 
located on the superior aspect of the ER, the ER can serve as a guide to facilitate device 
delivery to the FO, allowing the device to glide along the valve and onto the ER (Figures 
1.2B and 1.2C). 
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Figure 1.2:  In the diagram on the left (A), the green arrows depict the IVC approach to 
transseptal punctures.  The image on the top right (B) shows the FO and ER.  The image 
on the bottom right (C) shows a patent foramen ovale in the FO, with the ER adjacent to 
the FO. ER – eustachian ridge, FO – fossa ovalis, IVC – inferior vena cava  
 
The ER is a prominent rise between the FO and the CS ostium (Os) [29, 30] The superior 
and posterior margins of the FO are enfolded to produce the prominent muscular 
protrusion on the endocardial surface.  The FO lies next to the aorta, making transseptal 
punctures difficult. [31] Bordered by septal tissue and the ER, the FO is typically slightly 
recessed (Figures 1.2B and 1.2C).	  These structures can either facilitate or inhibit the 
operation of a medical device, either directing it in the intended direction or preventing it 
from being placed in the desired location.   
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Current catheter delivery systems face challenges in reaching the FO and conducting 
transseptal punctures.  Pectinated muscles adjoin the ER, which itself is pronounced and  
moves with each contraction.  The pectinated muscles adjacent to the FO are composed 
of undulations that are capable of restraining the tip of a dilator or catheter (Figure 1.3). 
Dilator tip dimensions are sized to only allow a transseptal needle to pass.  This small tip 
size also increases the chance of binding in these muscles if the tip is placed incorrectly.   
 
Figure 1.3:  This image shows the catheter dilator and sheath in the RA.  The red 
rectangle contains pectinated muscles that border the ER.  ER – eustachian ridge, RA – 
right atrium   
During transseptal punctures, the FO is manipulated extensively.  Both its size and 
thickness contribute to changes in the amount of compliance when force is applied 
(Figure 1.4). A large amount of compliance in the FO, coupled with a lack of compliance 
in the much thicker septal wall, can result in concentration of the transseptal force on the 
FO.  
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Figure 1.4:  The image on the left (A) shows deformation of the FO at the point of 
needle puncture in the LA. The image in the center (B) shows a transseptal puncture at 
the time of dilator insertion, with deformation of the FO (red oval) and a tight fit between 
the dilator and the FO.  The image on the right (C) shows 3 areas: 1, the septal ridge 
around the FO; 2, the thin and highly compliant nature of the FO; and 3, the ER. ER – 
eustachian ridge, FO – fossa ovalis  
  
Dilator tips enable practitioners to confirm anatomic location by tenting the FO.  Once 
tenting is achieved, a transseptal needle can be advanced through the FO (Figures 1.5A 
and 1.5B).  The large amount of tenting that is usually required and the compliance of the 
membrane draw into question how much force the FO is able to tolerate before the 
procedure fails.  Though necessary to perform transseptal punctures, FO tenting—
combined with excess extension of the transseptal needle tip into the LA—can result in a 
risk of cardiac tamponade.   
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Figure 1.5:  The image on the left (A) shows the view from the LA of the FO at the point 
of needle puncture.  The image on the right (B) shows the simultaneous view from the 
RA at the point of needle puncture. FO – fossa ovalis, LA – left atrium, RA – right atrium 
 
The very close proximity of the FO to both the right superior pulmonary vein (RSPV) 
and the right inferior pulmonary vein (RIPV) makes it challenging to reorient device tips 
after transseptal punctures (Figure 1.6). 
 
Figure 1.6:  In the diagram on the left (A), the green arrows depict the path of device 
delivery to the PV originating from the FO.  The image on the right (B) shows LA sheath 
placement after a transseptal puncture, with a guidewire introduced into the RSPV. FO – 
fossa ovalis, LA – left atrium. PV – pulmonary vein  
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Devices whose total deflection is limited, or whose deflection is located more proximally 
in the shaft, the resulting tip changes make it impossible to orient the device in a way that 
facilitates catheter introduction into the right PVs.  Consequently, the FO needs to be 
manipulated more.  Moreover, an incorrect puncture site location can increase the 
difficulty of introducing a catheter into the right PVs.   
Once a transseptal puncture is complete, the tissue is stretched over the outside diameter 
of the dilator and onto the outside diameter of the sheath (Figure 1.5B).  This transfer of 
force, the overall diameter of the sheath, and manipulation of the device in the LA can all 
contribute to the possibility of tearing the FO.  As the sheath is deflected and the device is 
introduced into the LA, the resulting forces on the sheath push and pull the FO.  If these 
forces become excessive, the FO can tear (Figure 1.7).   
 
Figure 1.7:  Example of potential complication as a result of catheter navigation 
performed in a swine showing FO tearing due to excessive deflection force from a 
delivery sheath attempting to navigate into a PV.   
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This step in the procedure prompts additional consideration of the use of the transseptal 
needle in the LA.  The transseptal needle extends beyond the tip of the dilator.  The 
amount of extension is dictated by the interference fit of the diameter on the needle shaft 
to the internal diameter reducer in the dilator tip.  Given the large amount of needle 
extension and the relative thickness of the FO, future device designs must improve the 
needle tip to reduce the risk of cardiac tamponade, while still preserving the ability to 
achieve successful punctures.  Clearly, anatomic variations can have an impact on the 
ability to conduct transseptal punctures and on possible complications.   
Such variability in anatomic structures—combined with current device limitations in 
sheath size and in needle, length, and deflection capabilities—require continued 
advancements in order to decrease the risk to patients.  Device developers must continue 
to collaborate with electrophysiologists.  A partnership between engineers and health care 
providers is critical for improving patient outcomes.   
Coronary	  Sinus	  
Arrhythmia ablation procedures commonly involve the CS. [32]  Its ostium is located on 
the opposing side of the ER.  In addition, the thebesian valve is located at the CS ostium 
(Figure 1.8). Inferior to the CS ostium, anatomic structures can be of various shapes and 
sizes. [33]   
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Figure 1.8:  In the diagram on the left (A), the green arrows depict the device approach 
originating from the IVC into the CS ostium.  The image on the right (B) shows the 
regional anatomy in the area of the CS bordered by the thebesian valve, including the 
IVC catheter introduction point. CS – coronary sinus, IVC - inferior vena cava.  
Clearly, anatomic factors can increase the complexity of device delivery.  The CS ostium 
resides in a deep pocket that is bordered by the ER, making catheter tip placement 
challenging.  The location of the CS ostium relative to the IVC, along with the size of the 
ostium, can also present challenges.   
To enter the CS, devices must have a high degree of deflection; furthermore, the region 
of deflection must have a small radius.  With devices whose deflection is located more 
proximally in a stiff shaft and whose diameter is 8-French or larger, it will be more 
difficult to orient the tip so that it aligns with the CS ostium (Figure 1.9). 
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Figure 1.9:  In this image, the green arrow depicts the device approach originating from 
the IVC.  IVC = inferior vena cava 
 
Further design work is needed to develop devices that can deflect in a small radius, 
allowing the catheter tip to be oriented in such a way that it can align with the CS ostium.   
Right	  Atrial	  Appendage	  
RA ablation is required in instances of AF in which the cycle length recorded in the RAA 
is shorter than is the cycle length recorded in the left atrial appendage (LAA).  The RAA 
location near the ostium of the IVC prompts the need to deflect devices (Figure 1.10A).  
The appendage can be a large structure; it is composed of very thin tissue as well as 
pectinated muscle and a sagittal band (Figures 1.10B and 1.10C).   
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Figure 1.10:  The diagram on the left (A) shows the approach to the RAA through the 
IVC.  The image on the top right (B) shows the large size of the RAA and pectinated 
muscles.  The image on the bottom right (C) shows the pectinated muscles and thin 
tissue. 
Given the thin tissue of these anatomic structures, devices need to have very smooth tips 
that do not focus force into a point. With devices that have a rigid shaft, the risk of 
perforating the RAA is greater, because of the higher transfer of force.  In contrast, with 
devices that have a compliant tip at the distal end, the tip can bend, thereby lessening the 
chance of perforating the RAA. 
Ablating	  left	  atrial	  structures:	  	  PV,	  MI,	  and	  LAA	  Roofline	  
The LA has a venous component, along with a vestibule and an appendage.  The  
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additional 4 venous orifices serve as corners to the atrium.  The vestibule surrounds the  
mitral ostium.  The LAA is typically a small extension that originates adjacent to the 
mitral valve annulus and the left PVs.   
In the atrial areas, the anterior wall behind the aorta is commonly thin and can be torn 
during transseptal punctures. [35] The thicker parts of the LA are on the superior wall.[36]  
The ostium of the right PVs are adjacent to the plane of the atrial septum.  The tissue that 
makes this transition is smooth.  The target of PV isolation is a muscular sleeve that 
extends into each vein and ends inside the sleeve.  The role of the sleeve has been 
reviewed in other studies. [37, 38]  The organization of electrical activity from the PV is 
well known. [39, 40]    
The smooth wall of the LA facilitates a uniform drag of the catheter tip against the tissue.  
The size of the LA is conducive to catheter tip placement against the tissue surface.  But 
the formation of a small gap is possible; complex cardiac navigation systems do provide 
some guidance as to gap location, yet it might not be sufficient.   
LA ablation can occur in a number of different locations and can be prompted by 
continuous electrical activity, with a minimum duration of 100 ms [41] and either 
fractionated or fragmented electrical activity.  [42]  
Left	  atrial	  pulmonary	  veins	  
PV isolation is a key step in treating patients with all forms of AF.  Of note, the muscle 
sleeves in the ostial opening of all 4 PVs emit ectopic beats.  Electrical isolation of each 
vein is now the standard of care for treating AF, using either cryogenic or radiofrequency  
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ablation. [29, 30, 31] In electrical isolation procedures, both ablation and diagnostic devices 
are used around and inside the PVs.  The types of devices include guidewires, balloons, 
diagnostic catheters, and focal ablation catheters.   
The ostia of the right PVs are adjacent to the FO.  The ostial opening of the PV is a 
smooth surface. The close proximity of the PV ostia to the FO, and the sharp angle 
between them make it hard to orient a catheter through the puncture site and into the PV 
(Figure 1.11). 
 
Figure 1.11:  In the diagram on the left (A), the green arrows depict the directions of 
device introduction originating from the FO into the LA pulmonary anatomy.  The image 
on the top right (B) shows the left PV ostium.  The image on the bottom right (C) shows 
the right PV ostium. FO – fossa ovalis, LA – left atrium, PV pulmonary vein 
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The ostia can comprise ridges and are adjacent to each other on opposing sides of the 
atrium.  The shape and orientation of the PV can vary; other anatomic structures can be 
atypical.  Variations can include differences in ostial size and the existence of a common 
shared ostium.   All of these factors can affect the effectiveness of the devices used to 
electrically isolate the tissue.  
The PVs interface with guidewires, sheaths, balloons, and focal ablation catheters.  The 
location of the transseptal puncture can have a dramatic effect on the ability to place the 
catheter tip in the ostium of the PV, especially because the distance from the FO to the 
ostium is short.  In addition, the orientation of the opening of the PV is directed in a way 
that can result in the need to twist the guidewire to allow it to migrate inside the PV 
(Figure 1.12A).  This anatomic orientation of the FO and the PV illustrates the 
importance of a sheath that has a small radius of deflection at the tip in order to facilitate 
guidewire insertion.   
Catheter placement into the PV is also affected by the contour of the catheter tip.  The 
angle of the catheter’s approach might require anatomic guidance to properly position the 
tip (Figure 1.12B).  This device-tissue interface shows the importance of a smooth, 
contoured tip.  
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Figure 1.12:  The image on the left (A) shows the catheter sheath and the use of a 
guidewire for placement into the RSPV.  The image in the center (B) shows the 
introduction of the catheter tip at the PV ostium.  The image on the right (C) shows the 
retraction of the catheter sheath to the FO and the introduction of a balloon catheter.FO – 
fossa ovalis, RSPV – right superior pulmonary vein, PV – pulmonary vein   
The complete insertion of the ablation catheter is affected by its size and by the size of 
the atrium.  The proximity of the FO to the PV can limit the ability to have both the 
sheath and the catheter in the chamber (Figure 1.12C).  Limiting the distance of the 
therapeutic region of the catheter would provide greater latitude for use of the entire 
system in the atrium.  Operation of these devices on the right side of the atrium is one of 
the more challenging steps of the procedure.   
Performing the same steps on the left side of the atrium requires different device 
performance.  The orientation of the FO to the left PV ostia (as compared with the right 
side of the atrium) is more conducive to device delivery.  Guidewire introduction is 
typically facilitated by the nearly linear orientation of the FO to the PV ostium (Figure 
1.13A), which allows the guidewire to be placed and lodged in the PV (Figure 1.13B).  
The alignment of the FO and left PVs allows for easy catheter introduction into the LA 
and sufficient room to operate the device, thereby reducing the stress on the FO and 
	  
	  
lessening the demands on the sheath (Figure 1.13C). For balloon-based devices, which 
require more area to operate than do focal ablation catheters, the alignment of the FO and 
left PVs is of particular importance.   
	  
Figure 1.13:  The image on the left (A) shows the catheter sheath and the use of a 
guidewire for placement into the LSPV.  The image in the center (B) shows the 
placement of the guidewire into the PV ostium. The image on the right (C) shows the 
introduction of the balloon catheter across the LA.  LA – left atrium, LSPV – left superior 
pulmonary vein, PV – pulmonary vein 
 
Once the catheter is delivered into the PVs, therapy delivery remains challenging.  For 
example, balloon-based therapeutic devices are larger, with only a limited amount of 
deflection ability, so they require more room to operate.  Given the orientation of the 
transseptal puncture to the ostium of the PV, the balloon is able to fully occlude the vein.  
However, uniform cooling may not be achieved, because the balloon’s orientation is 
limited by the FO’s orientation to the PV’s muscular sleeve (Figure 1.14). 
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Figure 1.14:  In this image of a balloon-based LA RSPV occlusion, the sheath is 
retracted to accommodate the ablation catheter (red circle).  The catheter orientation 
(green arrow 1) is not aligned with the PV ostium orientation (green arrow 2). LA – left 
atrium, PV – pulmonary vein , RSPV – right superior pulmonary vein 
 
These anatomic challenges accentuate the importance of having an acute distal deflection 
segment on the ablation device—in order to improve catheter tip orientation to, and 
alignment with, the PV ostium.  Such challenges also jeopardize the ability of the sheath 
to maintain its placement in the LA.  Decreasing the length of the distance between the 
distal tip of the sheath and the proximal end of the balloon would allow more sheath to be 
retained in the LA.  The sheath must have a very distal deflection control with an acute 
radius of deflection.  The smooth wall of the atrium facilitates placement of the ablation 
catheter.   
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If additional lesions are necessary beyond PV isolation, they can be created in the LA in 
the form of a linear lesion along the roofline or a mitral isthmus lesion, or via ablation of 
the LAA.   
Left	  atrial	  appendage	  	  
Many times, the LAA is a site for the deposition of thrombus. A stroke is a possibility if 
the thrombus is able to dislodge and travel to a part of the vasculature that supplies blood 
to the brain.  The LAA is oriented on the opposing side of the LA from the FO, making 
device delivery less challenging (Figure 1.15A).   
 
Figure 1.15: In the diagram on the left (A), the green arrow indicates the approach to the 
LAA from the FO.  The image on the top right (B) shows the position of the LAA 
relative to the MVA and the presence of pectinated muscle. The image on the bottom 
right (C) shows the position of the LAA relative to both the MV and the LSPV.FO – 
fossa ovalis, LAA – left atrial appendage, LSPV – left superior pulmonary vein, MV – 
mitral valve 
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For achieving and retaining device placement, the opening of the LAA can be 
challenging.  The ability to place a focal ablation device at the ostial opening is 
complicated by the presence of prominent ridges in the ostial area of the LAA.  Focal 
devices for performing point-by-point ablation around the opening are difficult to 
operate.  Alternatively, devices that encircle the LAA, or that occlude it, preclude the 
need to create point-by-point lesions and remove the complexity of attempting to place a 
catheter tip on a ridge structure.   
 
Figure 1.16:  This image shows the catheter shaft circulating around the LAA ostium; 
the red circle depicts the ridge between the LAA and LSPV. LAA – left atrial appendage, 
LSPV – left superior pulmonary vein   
Devices that deploy into the LAA and then place the therapeutic region at the opening are 
able to encircle the opening (Figure 1.16). Focal ablation devices need the ability to apply 
sufficient force on the tissue for lesion generation, without slipping into the pectinated 
muscles of the LAA interior.   
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Dynamically shaped ablation devices that could occlude the LAA would have an 
advantage: they might be able to maintain position and sufficient force for lesion 
generation.   
Mitral	  isthmus	  and	  roofline	  ablation  
The mitral isthmus (MI) is a region of tissue that borders the annulus of the mitral valve 
and borders the LAA, and then rises over the ridge toward the left PV (Figure 1.17A).  
This is a common area to create a contiguous lesion in, which helps terminate conduction 
patterns in patients with AF in whom PV isolation is not sufficient. [32, 33, 34]    
 
Figure 1.17:  The diagram on the left (A) shows the MV in the LA.  The image (B) notes 
various structures, including the MVA, which serves as the starting point for creating a 
linear lesion in the MI.  LA – left atrium, MV – mitral valve, MVA - mitral valve 
annulus.  
The creation of the MI or roofline linear lesion is affected by even a minor amount of 
anatomic movement of the MI with each contraction, making catheter tip placement on  
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the ridge difficult.  Any anatomic movement changes the force on the catheter tip and can 
contribute, at times, to a temporary loss of sufficient contact for lesion creation.  The 
ability to maintain tissue contact is a byproduct of the amount of force on the catheter tip.  
For MI linear lesion creation, given the orientation of the FO in relation to the MVA, the 
catheter tip must be able to reach to the MVA, and the deflection must be able to place 
force on the catheter tip (Figure 17B).The presence of a ridge is an additional 
complicating factor: the shape of the ridge can be pointed, making it difficult for the 
catheter to be placed on it.   
To ensure necessary contact when creating a linear lesion, a focal catheter may be used 
against a supporting structure, such as another catheter (Figure 18A) or the wall of the 
atrium (Figure 1.18B).	  
	  
Figure 1.18:  The image on the left (A) shows MI lesion creation originating at the 
MVA.  The image on the right (B) shows creation of a roofline linear lesion. MI – mitral 
isthmus, MVA – mitral valve annulus 
A focal ablation catheter has the advantage of adaptability. This device design could be 
extended to include repositioning of electrodes, softening of the tip, and better deflection  
26 
	  
	  
capabilities all of which could widen application across an array of atrial anatomies,  
resulting in an improvement in energy delivery.  
Conclusion	  
Understanding how ablation devices interface with tissue and anatomic structures can 
make a crucial difference in their therapeutic application.  Anatomic structures vary from 
person to person. Within each person, the endocardial surface changes shape with each 
heartbeat and can prompt catheter migration, making it difficult to know exactly where 
the device was placed and what is happening at the device-tissue interface.  By using 
Visible Heart® methods to directly visualize the device-tissue interface in fresh 
reanimated human hearts, we assembled and analyzed an array of illuminating images, 
providing a critical aid to clinicians and medical device designers alike.  
The tools that have traditionally been used to treat patients with AF have numerous 
limitations, all of which lengthen ablation procedure time and increase the likelihood of 
disease recurrence.  Future research in this field needs to focus on reducing the risks of 
transseptal procedures, increasing catheter mobility, enhancing the anatomic precision of 
catheter tip placement, , and improving imaging capabilities.  Studies must investigate 
methods for improving transseptal punctures, reaching targeted anatomies with 
therapeutic devices, and assessing the effectiveness and quality of lesions at the point of 
their creation.   
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Preface:	  	  	  
This study was motivated by the first chapter, in which we observed the transseptal 
puncture under direct visualization.  As commented, the methods lacked the ability to 
quantify the amount of force required to perform the transseptal puncture.  The ability to 
correlate the performance of medical devices in performing the transseptal puncture 
between animal to human has been missing as a predictive indicator of human device 
performance.  This study devised a set of methods to quantify the transseptal puncture 
procedure using clinical devices and then derived a correlation between swine and 
human.  This enables the ability to understand the translation between models and to 
offer predictions of anticipated performance in a human.  The material in this chapter has 
been published in the Journal of Interventional Cardiology – a peer reviewed journal.   
For this study, I was responsible for study design, data analysis, manuscript editing. 
Stephen Howard contributed to study design, method creation, data collection, data 
analysis, and manuscript creation.  Stephen Quallich also contributed to method 
development, data collection, data analysis, and manuscript editing.  Paul Iaizzo provided 
editing.   
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Summary	  
Background:	  	  
Transseptal puncture is a common procedure that gains access to the left atrium, allowing 
percutaneous mitral valve repair, left atrial appendage closure, and left-sided ablations. 
The basic approach has not changed in many years, however the frequency of transseptal 
punctures and the size of devices are increasing with emerging treatments. This study 
examined the mechanical response of the fossa ovalis as a result from different 
transseptal device sizes in both swine and human. 
Methods	  and	  Results:	  	  
A broad size range of transseptal devices (4F-18F) were advanced through atrial septa of 
swine hearts; some devices were inserted in both swine and human hearts using 10F 
catheters. Greater forces were required to puncture through the septa of human hearts 
compared to those of swine. Larger catheters used in swine hearts required greater force 
to advance them through the septa, causing greater dilation of tissue and sometimes 
tearing the floor of the fossa ovalis; analyses indicated an exponential increase in size of 
the iatrogenic atrial septal defect. Specific tissue property testing of the septum primum 
showed that this tissue sheared at a lower exerted force in a superior to inferior direction. 
Conclusions:	  	  
The results of this study mean that this data can be used in the creation of a swine based 
model that could be used as a predictive indictor of the human response.  In addition, the 
greater forces required to conduct the transseptal warrant additional work to study if these 
increased forces place additional risk of anatomical damage related to possible  
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perforation of the atrial wall.  Finally, these results mean that an increased size in the 
atrial septal defect will require additional study to understand the long term impact on 
tissue healing at the puncture location. 
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Introduction	  
Transseptal punctures (TSP) have been performed since the 1960s for a variety of clinical 
procedures43. The avascular fossa ovalis (FO) in the atrial septum provides a location, as 
this tissue is thin allowing for deformation (tenting) of the tissue that is visible on 
fluoroscopy to ensure appropriate anatomical location prior to performing the puncture to 
the left atrium. It should be noted that other routes (e.g., through the arterial vasculature 
or transmyocardially) may elicit associated complications or be more difficult relative to 
a transseptal approach44. To perform a TSP, access to the right atrium is obtained through 
the venous system, then transseptal sheaths are advanced through the vasculature and into 
the right atrium. The placement of the sheath onto the FO is identified by watching for a 
characteristic “jump” of the dilator tip following retraction and dragging of the 
transseptal equipment inferiorly. After the FO has been located, the tenting can be 
generally visualized through fluoroscopy and, more commonly, echocardiography45, 46. A 
physician will tend to look for the most optimal portion of the septum to puncture based 
on the type of left atrial procedure that needs to be conducted. Additionally in some 
patients, more than one puncture may be conducted to simultaneously advance different 
types of catheters into the left atrium. Nevertheless, the optimal placement of the 
puncture location is very important, as it will commonly affect the ultimate success or 
ease of a given clinical procedure47.  
 
The complication rates associated with transseptal punctures are cited to be as low as 
0.74% of procedures intraoperatively48. Yet, the post-operative outcomes are considered  
32 
	  
	  
separately and incidences of remnant interatrial shunts have been reported. For example, 
McGinty et al. presented a review indicating prevalence of iatrogenic atrial septal defects 
(IASDs) to be as high as 87% post procedure and, at an 18-month follow-up, incidences 
were reported as high as 15%49. Although the authors suggest that most of these created 
holes were resolved over time and the IASDs were not associated with clinical issues 
such as embolism, cyanosis, or right heart failure, they could still present issues 
especially if one assesses potential new procedures involving TSPs with larger sheaths49.  
As mentioned above, there are a number of procedures that require a TSP including left-
sided cardiac ablations, percutaneous mitral valve repairs, mitral balloon valvulotomies, 
left atrial appendage closures, and certain ventricular assist device placements44, 50-59. 
These procedures along with some newer and future procedures, including left ventricular 
endocardial pacing and percutaneous mitral and aortic valve implantation, could 
potentially bring about a greater prevalence of TSPs and thus higher incidences of 
potential complications60-62. As cardiology procedures have progressed, the range of sizes 
for transseptal devices has increased. To date, the smallest transseptal devices typically 
are 4F and range up to the largest reported of 22F49, 61. This latter size range has 
prompted discussions regarding what the FO is capable of tolerating, a topic addressed in 
previous publications49, 53, 55, 63. Yet, we consider here that a detailed study investigating 
the elastic tissue properties of the FO and the impact of the various sized catheters on 
IASD formation is necessary to help understand clinical limits.  
In addition to the puncture that is created in the FO, manipulation of catheters and tools  
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across the septum may result in the tissues being stretched and/or torn, resulting in larger 
IASDs. A previous study relative to this topic was performed by Saitoh et al. with a 
mitral valve clip procedure under echocardiography51. The subsequent holes created and 
identified were elongated and elliptical (not circular), suggesting that the simple puncture 
forces were not the only strains being placed on the septum, but rather some radial/shear 
forces applied by the catheter could potentially cause tears in an axial direction. Since the 
utilization of swine hearts as a model for TSP studies has been reported previously, we 
also believe it provides a good anatomical basis for our study. Yet, by additionally 
utilizing both ex vivo swine and human hearts for a subset of our experiments, multiple 
variables could be studied and a relation to human cardiac anatomy can be specifically 
assessed64-66.  
Finally, the biomechanical characterization of the heart, as a whole, is currently 
underway by numerous laboratories. For instance, interest in tissue engineered heart 
valves has led to the study of valves to better mimic their behavior67, 68. However, studies 
assessing the tissue properties of the FO and methods to reduce damage during such 
procedures, to the best of our knowledge, are nonexistent. Such information would be 
quite useful for improving the understanding of the shear/tear forces and biomechanical 
properties to attain a complete view of IASD creation. As technology continues to 
advance, the role of computational modeling in device development and personalized 
medicine will likely become readily available and important, and the data we describe 
here will be critical inputs for this development69.  
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Methods	  
Obtaining	  tissue	  and	  preparation	  
Swine hearts (n=48) were obtained fresh and were transported on ice and then dissected 
within 8 hrs post excision. The right and left atria were opened to expose the interatrial 
septum while keeping intact the tissue surrounding and supporting the FO. The isolated 
cardiac tissues were warmed to 37°C using a circulating water bath. Images of the FO 
were taken pre- and post- puncture. 
Human hearts were received as a donation for research to the University of Minnesota 
from organ donors whose hearts were deemed not viable for transplantation (via 
Lifesource, St. Paul, MN, USA). Table 2.1 provides brief medical histories of the donors 
including these cardiac conditions: one with atrial fibrillation, one with hypertension, and 
one with an unspecified “heart problem.”  
Table 2.1. Baseline characteristics of human hearts (n=7) 
 
Demographic Measurement 
Male (%) 57.1 
Age (years) 58.4±5.7 
Weight (kg) 86.0±30 
Height (cm) 168.7±7.7 
Heart Weight (g) 428±130 
	  
	  
    Fossa size: 
 
Superior/inferior (mm) 20.8±6.2 
Anterior/posterior (mm) 15.7±6.2 
Thickness (mm) 0.68±0.27 
 
Exclusion criteria for testing included lack of an intact atrial septum and other congenital 
abnormalities that would disallow the suction device to be implemented. These hearts 
were warmed with 37°C saline. 
Catheter	  and	  fossa	  holder	  method	  	  
A suction device on a positionable arm provided circumferential adhesion surrounding 
the FO to hold the interatrial septum in a secure manor (Fig. 2.1).  
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Figure 2.1:  Radial adhering suction device for stabilization of the atrial septum for 
tissue puncturing. (A) Force testing machine with transseptal device attached and 
puncturing the atrial septum. (B) Close-up view of the atrial septum and stabilization 
device employed for puncturing.  
 
The devices used in these experiments were composed of a dilator and sheath, and had 
internal diameters of 4, 8, 10, 12, 16 and 18 French, according to manufactures’ 
specifications. Only the 4F, 8F, 10F and 12F devices were indicated for transseptal 
applications, while the remaining two devices had specified alternative uses; their  
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employment in these investigations allowed for testing of larger diameter sheaths. The  
specific measurements of the outer diameter as they relate to the catheter size are listed in 
Table 2.2. 
Table 2.2. Size and dimensions of catheters 
Manufacture Labeled 
Catheter Size 
Dilator OD 
(mm) 
Sheath OD 
(mm) 
4F 1.8 2.2 
8F 3.2 3.8 
10F 3.6 4.1 
12F 3.9 4.8 
16F 5.3 6.5 
18F 6.0 7.2 
*OD=outer diameter 
Catheters were trimmed to a length of 15cm and, if curved, they were straightened to 
keep the structural integrity yet provide a linear direction of force normal to the FO. The 
dilator and sheath were bonded together with ultraviolet cure adhesive (Loctite, Henkel, 
Düsseldorf, Germany) at the cut end of the catheter. The internal lumen of the dilator 
remained unobstructed to allow for a Brockenbrough® (BRK, Medtronic, Inc., Fridley,  
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MN, USA) transseptal needle, cut 18cm from the tip and straightened to protrude from 
the dilator tip, as it would in clinical practice. Alternative designs were used for the 4F, 
16F and 18F devices, since they would not allow for proper protrusion of the needle tip 
beyond the dilator tip. The end of a Brockenbrough needle was separated from the main 
shaft and adhered into the tips of each of the dilators of those catheters with a stiff metal 
rod through the dilator to provide mechanical support for the needle tip (Fig. 2.2).  
 
 
Figure 2.2: Schematic of transseptal devices used for testing. The dilator was seated into 
the sheath and attached at the proximal end via adhesive. The center lumen was kept clear 
for a needle to be placed through it and protrude from the distal tip.  
 
The catheters were either clamped or inserted into a connector attached to a load cell for 
obtaining puncture forces.  
Tenting	  and	  puncture	  testing	  
A circumferential suction device was attached to the atrial septa of either swine or human 
hearts (Fig. 2.1) to allow for continuous and repeatable fixation of the FO, as noted 
above. The device was locked into place with the FO in the center of the suction ring, and 
the FO was placed perpendicular to the trajectory of the transseptal catheter.  
The forces required to puncture and tent the FO at various locations were obtained by  
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using mechanical force testing systems (Instron, Norwood, MA, USA; Chatillon 
TCD225, Largo, FL, USA). The relative locations of tenting and punctures were defined 
in relation to the superior, inferior, anterior, and posterior orientations (Fig. 2.3).  
 
 
Figure 2.3: Location of the fossa ovalis (FO) in relation to other anatomy within the right 
atrium (RA): the inferior vena cava (IVC), and the coronary sinus ostium (CS Os). The 
numbers indicate various puncture locations: (1) center, (2) inferior, (3) posterior, (4) 
superior, and (5) anterior. 
 
The shortened catheters were affixed to the load cell so that their trajectory was normal to 
the floor of the FO. Following stabilization of the FO with the suction device, the 
catheters (without the needle protruding from the dilator) depressed the FO to a depth of 
8mm for swine hearts and 12mm for human hearts at a rate of 254mm/min and then 
retracted to the starting position. The difference in the protocol between human and swine  
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experiments was related to the identified differences in the tissue compliance between the 
swine and human tissues based on pilot studies of the tissue (data not shown). The first 
tenting location was the center of the floor of the FO, followed by the inferior, posterior, 
superior, and anterior regions. Then the catheters were driven through the FO with a 
transseptal needle protruding from the dilator at a rate of 254mm/min at various locations 
on the FO, beginning with the center and followed by subsequent puncturing at alternate 
locations.  
Initial analyses of the force versus distance relationships indicated that the largest forces 
required for transseptal puncture were when the tips of the needles, tips of the dilators, 
dilations of the septum, and tips of the sheaths were going through the septum (Fig. 2.4).  
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Figure 2.4: Characteristic force verses distance graph during fossa ovalis puncturing. 
Note the distinctive peaks during each transition of the dilator and sheath; upon reaching 
a new layer, the force increases due to the need for fossa ovalis expansions. 
 
The forces and distances were recorded by the system for each of these events for the 
various puncture locations. Following the punctures, the remnant holes were measured.  
Fossa	  shear	  force	  analyses	  
Additional swine hearts were obtained ranging from 400-650g in size (n=70). The atrial 
septum including approximately 5mm of tissue surrounding the floor of the FO was 
excised from each heart. Samples were randomized to size and direction groups, and the 
inferior or posterior portion of the musculature surrounding the FO floor was cut off (Fig. 
2.5A). The FO was punctured with a transseptal Brockenbrough® needle and then a 4F, 
12F, or 18F sheath was advanced through the septum. In all cases, the sheath and dilator 
were maintained in a perpendicular position relative to the floor of the FO via a custom 
fixture (Fig. 2.5B).  
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Figure 2.5: Schematic representation of the fossa ripping test setup. The muscular tissue 
adjacent to the septum primum (posterior rim of the fossa ovalis for posterior pulls and 
superior rim for inferior pulls) was cut off to allow the sheath to fully disengage from the 
atrial septum without consequence from the muscular portion of the atrium surrounding 
the floor of the fossa ovalis (A). The fossa ovalis was ripped by a catheter which was 
inserted through the floor of the fossa ovalis in the mechanical force tester (B). An 
example of the resultant force versus extension plot is shown in (C). 
 
While the side of the FO opposite the cut side was anchored, the sheath was pulled away 
from the base at a rate of 100mm/min causing it to rip through the FO, employing a 
mechanical force tester (Chatillon). These atrial septa were ripped towards the cut section 
of the septum in either a superior or posterior direction. The average sheath ripping forces 
were defined as the average forces while the septum primum was ripping. To illustrate, 
Figure 5C shows that the 10-19mm extension portion for this sample was defined as the 
average ripping force, while the peak sheath ripping force was the highest force recorded. 
Fossa ovalis dimensions, average ripping force, and peak sheath ripping force were also  
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recorded. 
Tensile	  testing	  
Swine atrial septa were harvested in the same way as described previously (n=16 
animals; n=41 samples). The FO was dissected into several (1-5) strips along either the 
superior/inferior or anterior/posterior directions. These strips were cut in a dog-bone 
shape and 2-0 silk sutures were tied to both ends (Fig. 2.6) for mechanical testing; the 
samples were pulled at a rate of 100mm/min until failure with a mechanical force tester.  
 
 
Figure 2.6: Example of prepared dog-bone shaped sample used for testing (A) and with 
2-0 silk suture attached while mounted in the testing pull tester (B).  
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The dimensions of each sample were recorded along with the strain at failure and peak 
force; the Young’s modulus was calculated. 
	  Statistical	  analyses	  
All data are represented as the mean±SE unless otherwise noted. Student’s T-tests were 
used for one-to-one comparison and ANOVA was employed for multi-group 
comparisons. Significance was determined with a p-value <0.05. 
Results	  
Tenting	  studies	  
The initial tenting experiments showed that the average forces required to tent and extend 
the septum primum by 8mm were greater for the human hearts compared to swine 
(199±30gf vs. 135±5gf respectively, p<0.001). By breaking down the data to assess the 
relative effects of location on the tenting forces, only one statistically significant 
difference was identified in the inferior portion of the FO, where the human tenting was 
significantly higher (145g±65g, n=40, vs. 292g±213g, n=8; p<0.01). The remainder of 
the species comparisons for each location were not significantly different (Fig. 2.7).  
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Figure 2.7: Forces required to tent the fossa ovalis by 8mm. Experiments were 
performed on excised human (n=8) and swine (n=40) hearts. (*=p<0.01, **=p<0.001) 
 
Yet, if one combines all tenting data per species, the swine hearts were shown to require 
significantly less force to tent the fossa regardless of the location (swine 138±5g n=180 
vs. human 199±30g, n=23, p<0.001). In general the lowest tenting forces were observed 
in the center of a given fossa, however the data were not significant (p>0.05).  
Puncture	  forces:	  human	  vs.	  swine	  comparisons	  
Human heart specimens were punctured only with the 10F catheter for comparison to the 
swine hearts. These punctures produced characteristic force versus distance plots, where 
the forces for the needle, tips of the dilator, and the sheaths to pass across the septum 
were easily observable as transient peak forces (Fig. 2.4). The other force recorded of 
interest was the maximum force seen during the dilation phase of the septum (i.e., when  
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the tapered portion of the dilator passed through the FO).  
When comparing the 10F catheter data between swine and human samples, the results 
showed a higher force required for each portion of the catheter (Fig. 2.8).  
 
 
Figure 2.8: Average peak forces required to pass various portions of 10F sheath through 
the septum primum in isolated septa of human and swine hearts. Significant differences 
were found between these two species when comparing the tip of the dilator, dilation, and 
sheath forces (*=p<0.01, **=p<0.001) 
 
The greatest difference between species was observed for the data between the peak 
forces of the tip of the dilator, requiring 240% greater forces for the human hearts. It 
should be noted that significant differences were found when comparing the average 
forces required to pass the various potions of the catheter through the septum for the tip 
of the dilator, dilation, and the sheath (p<0.01 for each; Fig. 2.8). 
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While assessing relative distributions of the peak protrusion forces for each portion of the 
TSP with a given catheter, we obtained a larger range of values for the human tissue 
studies compared to the swine tissues. The human data displayed a much larger 
distribution of force for the penetration of each portion of the assembly compared to 
swine data (Fig. 2.9).  
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Figure 2.9: Histogram of recorded peak forces required to traverse the septum with 
various portions of a 10F sheath. 
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Although this trend was seen for the tip of the dilator and sheath, the range for the needle 
puncturing produced a plot with similar distributions for both the swine and human data.  
Puncture	  forces:	  sheath	  size	  comparisons	  
The variability in the needle punctures alone resulted in an average puncture force of 
201±75gf (±SD) with the 176 punctures that were performed with the Brockenbrough® 
needle. To account for these variations in tissue performance, the subsequent portions of 
the sheath were normalized to the needle puncture forces. This was done to help 
determine the relative relationship between sheath sizes and resultant forces required to 
traverse the atrial septum. Subsequently, it was found that there was a direct correlation 
between catheter size and the forces required to pass through the septum. On average, the 
needle punctures required greater forces than either the passing of the tip of the dilator or 
the forces of dilating the tissues. ANOVAs were performed for each of the sheath 
sections and we found significant differences within each group with p-values<0.001 
(Fig. 2.10).  
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Figure 2.10: Relative forces required to traverse the atrial septum with various portions 
of a transseptal sheath of difference sizes. (Ŧ=p<0.001 based on ANOVA)  
 
The other notable trend observed was that the dilation forces were significantly less for 
each of the sheath sizes compared to both the passing of the tips of the dilator and/or the 
shaft of each sheath (p<0.02 in all instances).  
Following the punctures, images were taken of the resultant holes formed in the atrial 
septa. The minimum and maximum lengths were determined and plotted in relation to the 
outer diameter of the sheath. There was a positive correlation between the resultant hole 
sizes and the sheath sizes, as would be predicted. These data identified an exponential 
increase in resultant hole sizes (Fig. 2.11). 
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Figure 2.11: Minimum and maximum diameters of induced iatrogenic atrial septal 
defects, following transseptal punctures employing various sized catheters.  
 
Another important aspect when considering the transseptal crossing of devices relates to 
the differences in size between the various parts of a catheter system (i.e., the increase in 
transition diameters going from the dilator to the sheath). Intuitively the increase in the 
transition gap will require more force to move across the septum (Fig. 2.12).  
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Figure 2.12: Relative forces required to transition a catheter system through a septum 
from one portion of the transseptal puncture sheath to another. An increase in the cross-
sectional area of the relative portions of the catheter required more force to pass the 
catheter through a given septum.  
 
Increasing the diameter discrepancy between the subsequent portions of the TSP sheath 
requires an increase in force. Our data identified a plateau in forces with the increases in 
these cross-sectional area differences.  
Septal	  ripping	  forces	  
A summary of septum ripping by utilizing different sheath sizes is presented in Table 2.3.  
Table 2.3. Summary of fossa ovalis dimensions and sheath tearing forces listed by sheath 
size 
 
4 F 
(n=15) 
12 F 
(n=20) 
18 F 
(n=15) p-value 
	  
	  
Fossa ovalis thickness 
(mm) 1.1±0.1 1.2±0.1 1.1±0.1 0.727 
Superior/inferior width 
(mm) 16.5±1.1 14.3±0.7 15.7±1.2 0.241 
Anterior/posterior width 
(mm) 10.7±0.9 7.7±0.6 9.2±0.7 0.005 
Average tearing force (gf) 258±20 301±26 555±56 p<0.001 
Peak tearing force (gf) 344±26 417±37 704±72 p<0.001 
Heart weight (g) 487±10 464±13 451±10 0.563 
*Values are reported as mean±SE 
The chosen direction of induced FO ripping had a significant impact on the resultant 
average tearing force and peak tearing force (p<0.05). Superior-to-inferior induced rips 
required an average tearing force of 301±26gf, while those elicited in the anterior-to-
posterior direction required 363±41gf (Table 2.4).  
Table 2.4. Directional differences in septal tearing forces using a 12F sheath 
 
Superior-to-
Inferior 
(n=20) 
Anterior-to-
Posterior 
(n=20) p-value 
	  
	  
Fossa ovalis thickness (mm) 1.2±0.1 1.1±0.1 0.717 
Superior/inferior width (mm) 14.3±0.7 14.8±1.1 0.569 
Anterior/posterior width (mm) 7.7±0.6 7.9±0.7 0.480 
Average tearing force (gf) 301±26 424±41 0.012 
Peak tearing force (gf) 417±37 551±60 0.033 
Heart weight (g) 464±13 452±18 0.844 
*Values are reported as mean±SE 
Also, larger forces were required to rip the septa with larger sized sheaths (Fig. 2.13).  
 
 
Figure 2.13: Catheter size versus average tearing force. Tearing forces of the fossa ovalis 
increased with the usage of a larger diameter sheath, but did not significantly differ 
between the 4F and 12F sheaths (p>0.05). Error bars depict mean±SE. *p-value<0.001 
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The averages of the mean sheath tearing forces were 258±20, 362±25, and 555±56gf for 
the 4F, 12F, and 18F sheaths respectively; there were significant differences between the 
sheath sizes and sheath tearing forces between the 18F and 4/12F groups (p<0.001). 
Heart weight, animal weight, FO thickness, and width (superior-to-inferior) did not 
statistically differ between any of the groups (p>0.05). 
Tensile	  testing	  
We observed no statistical differences in the normalized peak forces, yet the superior-to-
inferior pull tests had higher average forces (136±11gf/mm2) than the associated anterior-
to-posterior pulls (116±10gf/mm2). However, the strain at failure was found to be 
significantly higher for superior-to-inferior pulls (90±7%) than for anterior-to-posterior 
pulls (55±7%)(p<0.01). Interestingly, the determined values for Young’s modulus were 
consistent along both axes with an average value of 32±3kPa (Table 2.5).  
Table 2.5. Summary of tensile testing stress, strain, and Young’s modulus 
  
Superior/Inferior 
(n=22) 
Anterior/Posterior 
(n=19) 
p-value 
Normalized peak force (gf/mm2) 136±11 116±10 0.178 
Strain at failure (%) 90±7 55±7 0.002 
Young’s modulus (kPa) 32±2 32±3 0.864 
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*Values are reported as mean±SE 
Heart weight, FO thickness and FO dimensions were not statistically different between 
the two groups (p>0.05, data not shown). 
Discussion	  
There are a number of different procedures requiring TSP including left-sided cardiac 
ablations, percutaneous mitral valve repairs, mitral balloon valvulotomies, left atrial 
appendage closures, and certain ventricular assist device placements44, 50-59. In many 
cases, the tissue of the FO is punctured and manipulated with large size devices. This 
study described a novel series of translational experiments that were performed to better 
understand the biomedical impacts of procedures that require the transseptal delivery of 
catheter systems through the atrial septum.  
The results of this study showed that a swine model  is helpful to determine the forces 
required for eliciting tenting and punctures, and that the forces measured were less than 
those seen in humans (121±11gf  vs. 146±26gf, p<0.001). Further, it is important to note 
that in both human and swine hearts, with the exception of potentially trying to tent the 
muscular septum, the relative septal location at which one chose to puncture was not 
material to the amount of force that may be required to produce tenting. The devices used 
in this study showed that, on average, the needle tented the septum 9.3±.3mm in humans 
and 9.8±.14mm in swine hearts (p=0.2), prior to ultimately perforating the septum. These 
outcomes demonstrate the ability of the swine model to serve as a proxy for humans.  
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In addition, the risk of cardiac tamponade continues to be a concern when conducting the  
TSP. Using the outcomes from this study, in an a heart ranging from approximately 
30mm to 50mm in diameter70-72, the needle will strain the FO approximately 25% of the 
distance into the left atrium before perforating and thus protruding into the left atrium. 
One should also keep in mind that this does not take into consideration that there is a 
slightly lateral but also superior trajectory on the needle when deployed through most 
TSP devices. These factors could potentially explain clinical incidents of left atrial 
perforation and resultant tamponade54.  
Within the puncture data, the relative variability was notably similar between the swine 
and human tissue groups; the standard deviation was 33% of the mean for human 
punctures and 37% for swine. Further, these values correlated to 75gf for the swine hearts 
and 90gf for human specimens, when assessing the Brockenbrough® needle puncture 
forces alone. Importantly, since the same needle was used, this variation was most likely 
due to the differences in cardiac anatomy or slight changes in tissue thickness. Another 
predictor of the force needed to traverse the septum was the difference in the diameter of 
the catheter system between the various steps of delivery (i.e., between the needle 
diameter and tip of the dilator diameter). Larger catheters resulted in greater forces 
required to go across the septum; similarly, it was observed visually that as catheter size 
increased so did the remnant holes that were created. Additional study of the relationship 
between remnant holes and catheter size is needed. These remnant holes may contribute 
to the ability for post-procedure healing. It has been reported that most IASDs close in  
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patients over time, but in some individuals this can take up to year49. 
An observation was made that subsequent stretching of these tissues required lower 
forces in swine, especially in the case of the dilator tips and dilation shafts. However, this 
is not necessarily the case for human tissue. Notably, the dilator tips deployed in the 
human septum required more than twice the force relative to swine tissue. This can be 
interpreted to indicate that there are clear distinctive differences between the atrial 
anatomies of these two species, which could potentially relate to the tissue structure or 
composition. Yet, it should be noted that another potential source of variability in our 
data could be associated with varied disease states and cardiac morphologies that were 
present within the donated human hearts.  
While medical device developers are striving to use the smallest types of delivery 
systems possible, catheter sizes in the realm of overall TSPs are getting larger due to their 
more complicated nature, e.g., with percutaneous mitral repair systems like the Abbott 
Mitra Clip being placed through a 22F catheter. Similarly, there is a major industry push 
to develop transcatheter mitral valve replacement systems that will be delivered via TSP; 
for comparison, the current transcatheter aortic valve systems utilize delivery catheter 
sizes ranging from 18F to 24F31. Needless to say, new mitral valve delivery catheters 
would probably be similar in size (if not larger) due to the difference in mitral and aortic 
valve circumferential areas. Thus when these technologies are deployed in humans, the 
clinician should have a good understanding of how the septum will react to the TSP51, 74. 
In clinical use, navigating transseptal catheters within the left atrium typically requires  
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sheath manipulation and risks FO tearing. Although procedures are trending toward  
larger sheath use, the incidence of FO tearing may be lower due to the larger sheer forces 
in larger sized catheters (Fig. 2.11). Further studies will need to specifically investigate 
FO tearing to fully characterize septal damages sustained by various clinical procedures. 
The tensile testing of the tissue showed significant differences in the maximal strains 
upon tissue ruptures. This along with the sheath ripping force differences in the superior-
to-inferior and anterior-to-posterior direction seem to indicate that there could be a 
particular alignment of tissue or fiber orientation that could potentially account for these 
differences. When a given sheath was being pulled through the floor of the FO in a 
superior-to-inferior orientation, it caused splitting between the tissue fibers oriented 
parallel to the direction of pulls, thus accounting for the reduced rip forces in the this 
orientation as well as the increased strains at failure in the tensile testing. We would 
predict from the ripping data that the superior-to-inferior direction would be weaker than 
the anterior-to-posterior direction, but this was not statistically supported by our data. 
Yet, this suggests that directionality of the rips in the FO is an important factor to 
consider. The literature reviewed showed that there are currently no histological studies 
of the FO for any species. We suggest that this may be an important pursuit of future 
research in order to understand the underlying micro-anatomy and what clinical 
implications it may have on the structure. Understanding the structural composition of the 
FO is a topic of ongoing research75. 
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Study	  limitations	  
The availability of human hearts for such studies is rare as one would expect, thus the 
majority of described experiments were performed with swine hearts. The use of swine 
hearts provided a method to test multiple catheter types, and we were able to relate these 
results to a subset of comparative human tissue trials.  
The true mimicking of physiological conditions imposes other issues related to force 
application on the catheter to puncture the atrial septum while accurately recording the 
displacement and the load. Using a consistent and repeatable suction device to hold the 
septum allows for a more controlled study with respect to load and displacement. Along 
with the consistency, the rate at which the tissue was pulled or punctured was kept 
consistent as a way to reduce the variables in the experimental setup.  
Conclusion	  
These novel translational in vitro studies of fresh heart specimens, both human and 
swine, provide a perspective on the challenges of conducting a transseptal procedure and 
present compelling data for further discussion on the device size constraints as more 
devices are constructed. In these designed experiments, we specifically observed that 
swine can serve as a reasonable model to mimic the human condition. In addition, 
advancements that are tested in the swine model can serve as a more rigorous application 
due to the more delicate nature of the swine anatomy.  
Funding Source: Medtronic, Inc. research contract (Mounds View, MN, USA); 
Medtronic had no involvement in study design, data collection/analysis/interpretation, or  
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report writing. 
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Preface	  
The inspiration for this study arose as a result of the previous two chapters.  The current 
method of performing the transseptal puncture has demonstrated a risk of tearing the FO 
and the current device designs pose a patient safety concern in that the dimensions of the 
devices along with the procedure technique may puncture unintended thin atrial tissue.  In 
addition, the recent adoption of  larger transseptal sheath sizes raise the question of what 
the limits are for the FO in its ability to resist tearing.  The introduction of radio 
frequency energy applied to the puncture device may promote resistance of the FO to 
tearing.   
Understanding how device size and puncture method interact with the FO are necessary 
to gain a better understanding of where the limitations may existing in the current device 
designs.  As part of understanding puncture methods, a prototype device is designed, for 
this study, to examine if the use of RF and a different puncture tool may aid in limiting 
FO damage in larger size devices.   
This chapter is designed to study device design to improve the transseptal puncture as a 
way to understand limitations that may exist when using different puncture methods for 
larger sized transseptal devices.  The material in this chapter has been submitted for 
publication to Journal of Interventional Cardiology. 
For this study, I was responsible for study design, conducting the data collection, data 
analysis, and publication creation. Stephen Quallich also contributed to method 
development, data collection, data analysis, and manuscript editing.  Megan Schmidt and 
Lars Mattison contributed to data collection, data analysis, and manuscript editing.   Paul 
Iaizzo provided editing.   
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Summary	  
Background	  
Left atrial access is required for transcatheter therapeutic approaches, such as mitral valve 
repair or replacement, left atrial appendage closure or ligation, and left heart endocardial 
ablation. Advancements in device designs have prompted changes in how catheter 
delivery systems perform transseptal punctures, including variations in sheath size (12-, 
16-, 18-, and 23-French) and the use of radiofrequency (RF) energy instead of 
mechanical force for device delivery. These changes have raised questions regarding the 
ability of the fossa ovalis (FO) and associated structures to withstand the biomechanical 
impact of transseptal puncture force.  
Objective	  
In our study, the primary objective was to quantitatively compare catheter delivery 
systems of different sizes (12-, 16-, 18-, and 23-French), with and without RF needles, 
for performing atrial transseptal crossing.	  Specifically,	  our	   focus	  was	  on	  the	  puncture	  force	  required	  to	  cross	  the	  septum	  and	  its	  impact	  on	  anatomic	  damage	  (tearing)	  of	  the	   FO.	   The	   data	   will	   influence	   device	   design	   as	   well	   as	   provide	   quantitative	  comparison	   of	   transseptal	   puncture	   and	   fossa	   ovalis	   compliance	   to	   different	   size	  devices. 
Methods	  
We analyzed the FO from 167 swine hearts that underwent transseptal punctures using 3 
devices: (1) a conventional curved transseptal needle (TN), (2) an RF transseptal needle 
(RFTN), and (3) a 5-French RF electrode with the tipped with a small segment of a TN   
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(ETN).  We assessed 4 different sized delivery systems (12-, 16-, 18-, and 23-French). 
Results	  
Mean puncture force for the dilator and sheath was significantly different for the 3 
methods for the 12-, 18-, and 23-French sizes (P < 0.05). Comparing needles, normalized 
mean puncture force of the TN (100 ± 54.6 grams) was significantly different from the 
ETN (64.9 ±3 2.9 grams) (P = 0.01), but not for the RFTN (76.4 ± 41.2 grams) (P = 
0.11). Comparing delivery systems, normalized mean puncture force of the 12-French 
system (100 ± 36.7 grams) was significantly different from the 23-French system (157.6 
± 66.2 grams) (P = 0.005), but not the 16-French system (128.8 ± 64.1 grams) (P = 0.09) 
or the 18-French system (86 ± 46.2 grams) (P = 0.30). The FO withstood greater peak 
tearing forces with a 23-French ETN device, as compared with all other sizes (P = 0.01).  
Conclusions	  
This study examined the performance of larger delivery systems and the impact of RF 
when conducting a transseptal puncture to better understand the how larger devices and 
the use of RF affect puncture and tear performance.  Our results are invaluable for 
clinicians and engineers designing new transseptal medical devices aimed at preventing 
anatomic damage.     
Keywords 
Atrial fibrillation, atrial fibrillation ablation, transseptal catheterization, transseptal 
puncture, left atrial access 
Abbreviations 
AF = atrial fibrillation, ETN = radiofrequency electrode with the tip of a transseptal 
needle, FO = fossa ovalis, LA = left atrium, RF = radiofrequency, RFTN = 
radiofrequency transseptal needle, TN = transseptal needle  
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Background 
	  
Ongoing development of new devices for cardiac therapies continues to rely on 
performing transseptal punctures to access the left atrium, a technique originally 
developed by Ross et al. and Cope et al. in 1959. [76, 77] But the increasing size of devices 
and their subsequent manipulation because of increasing procedural complexity are, more 
and more, challenging the limits of the fossa ovalis (FO), particularly its ability to stretch 
without tearing (Figure 3.1). 
 
Figure 3.1: The photo on the left (A) shows a swine heart’s torn fossa ovalis (FO), with a 
sheath through the opening made by a transseptal puncture, as viewed from the left 
atrium.  The photo on the right (B) shows a human FO puncture, as viewed from the left 
atrium. 
 
To successfully treat diseases, it is essential to have access to the anatomy in a way that is 
least likely to incur injury. Crossing the septum through the FO has a major impact on 
device delivery into the left heart and on the ability to reach key anatomic locations, such 
as the mitral isthmus, the mitral valve, and the pulmonary veins. The use of cryogenic 
balloon ablation therapies, and transcatheter mitral valve repair and replacement devices, 
requires 12- to 24-French delivery systems. Ideally, systems for accomplishing 
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transseptal punctures would allow the tissue to dilate and to be manipulated without 
tearing.  
Recent advancements in device designs have prompted changes in how catheter delivery 
systems perform transseptal punctures, including variations in sheath size (12-, 16-, 18-, 
and 23-French) and the use of radiofrequency (RF) energy instead of mechanical force. 
RF-based needles, intended to reduce the risk of cardiac tamponade, use RF energy 
delivered through the tip of the transseptal needle, typically at 10 watts for a period of 1 
to 10 seconds. [78-82]  
In our study, the primary objective was to quantitatively compare catheter delivery 
systems using different sheath sizes (12-, 16-, 18-, and 23-French), with or without RF, 
for performing atrial transseptal crossing.	  Specifically,	  our	   focus	  was	  on	  the	  puncture	  force	  required	  to	  cross	  the	  septum	  and	  its	  impact	  on	  anatomic	  damage	  (tearing)	  of	  the	  FO.	  We reviewed the puncture force and dilation strain of traditional and RF-based 
transseptal puncture systems; analyzed the impact of large-diameter delivery systems; 
and assessed a novel RF device using 4 different delivery system sizes.  
Methods 
 
Study population  
Fresh swine hearts (n = 167) were obtained (from Glencoe Family Farms, Glencoe, MN, 
and from the University of Minnesota’s Large Animal Veterinary Department, St. Paul, 
MN, and Visible Heart® Laboratory, Minneapolis, MN). Within 24 hours after the hearts  
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were excised, we dissected them. We first visualized the FO through the inferior vena  
cava. Then, we opened the right and left atria to expose the interatrial septum. We  
removed the septal tissue, taking care to keep intact all tissue surrounding and supporting 
the FO.  Each specimen included at least 5 mm of adjoining atrial septal tissue.   
Puncture	  devices	  	  
To perform transseptal punctures of the FO, we used 3 devices: (1) a conventional curved 
transseptal needle (TN) (Brockenbrough® Medical, Medtronic, Inc., Minneapolis, MN, 
USA) with a dilator and sheath; (2) an NRG® RF transseptal needle (RFTN) (Baylis 
Medical Company, Montreal, QC, Canada) with a dilator and sheath; and (3) a 5-French 
RF electrode with the tip of a TN (ETN) along with a dilator and sheath (Figure 3.2).  We 
used the 5-French ETN to understand whether an initial puncture with a larger RF tool 
would have an effect on the subsequent force for the dilator and sheath, particularly in the 
18- and 23-French sheath sizes.   
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Figure 3.2: The photo on the left (A) shows our study’s 3 transseptal puncture devices, 
from top to bottom (scale bar = 1 cm): a 5-French RF electrode with the tip of a 
transseptal needle (ETN), a radiofrequency transseptal needle (RFTN), and a 
conventional curved transseptal needle (TN). The diagram on the right (B) depicts the 
components of the 3 devices (purple = sheath, green = dilator).  
 
Each delivery system is comprised 3 parts: sheath, dilator, and needle. For dilator 
dimensions, we defined the distal diameter as the diameter of the opening at the tip of the 
dilator, taper length, as the distance from the tip of the dilator to the end of the tapered 
section of the dilator on the shaft of the dilator; and shaft diameter, as the diameter of the 
shaft of the dilator at the end of the tapered section. (Table 3.1).	  
Table 3.1: Dilator dimensions 	  
 
12-French 
TN & 
RFTN 
12-French 
ETN 
16-French 
TN & RFTN 
16-
French 
ETN 
18-French 
TN & 
RFTN 
18-
French 
ETN 
23-French 
TN & 
RFTN 
23-
French 
ETN 
Distal diameter (mm) 1.63 2.43 1.57 1.97 1.5 1.95 2.21 2.42 
Taper length (mm) 14.02 10.14 65.04 49.5 56.12 59.58 64.15 68.77 
Shaft diameter (mm) 3.56 3.5 5.36 5.32 5.82 5.8 7.57 7.59 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the 
tip of a TN  
	  
For sheath dimensions, the outer diameter was measured (Table 3.2).  
Table 3.2: Sheath dimensions  
 
Sheath size  
12-French 16-French 18-French 23-French 
Outer diameter (mm) 4.84 5.86 6.83 8.60 
 
Force	  testing	  	  
For all force measurements, both the puncture device and the septal tearing method used  
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the same load cell for force measurements. To measure the puncture and tearing force of 
the FO, we used the Chatillon TSD110 Digital Force Tester™ (Chatillon, Largo, FL, 
USA). We mounted the specimens as described by Howard et al. [84] After tissue 
mounting, we activated the tester with data logging to complete either the FO puncturing 
or the septal tearing. To determine maximum puncture force, maximum tearing force, and 
mean tearing force, we used MATLAB (MathWorks, Natick, MA, USA).  
FO puncturing 
To confirm the puncture location, we directly visualized the FO (Figure 3.3B). The 
selected needle or electrode was inserted into the dilator until it extended approximately 2 
cm past the tip of the dilator, then placed in close proximity against the FO, perpendicular 
to the center of the FO. The needle or electrode was extended past the tip of the dilator 
and placed against the FO. Then, the septum was mounted in preparation for puncture 
(Figure 3.3A). The system was advanced at a rate of 254 mm/min upon the FO until the 
needle, dilator, and sheath had fully crossed the FO. The remaining pieces of the delivery 
system were advanced across the FO, with all 3 devices, once the septum was punctured. 
The approach was similar with the RFTN. The RFTN was connected to the RF generator 
(Baylis Medical Company). RF energy was delivered using 10 watts while the entire 
system was advancing toward the fossa at a rate of 254 mm/min. The rate of movement 
was set to match the same rate as the conventional curved TN, in an attempt to match 
current clinical practice. Energy delivery was started before contact with the tissue and 
terminated after puncture.   
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Figure 3.3: The diagram on the left (A) depicts the setup for transseptal punctures, with 
the device positioned to be inserted through the fossa ovalis (FO) mounted on a plate; all 
3 components—sheath (S), dilator (D), and needle (N)—were oriented perpendicular to 
the specimen. The photo on the right (B) shows septal tissue prepared for puncture (red 
oval = the FO). 
 
With the ETN, a 5-French electrode using RF energy was delivered using 30 watts with 
the Medtronic Atakr® (Medtronic, Inc.) generator. The ETN was connected to the RF 
generator and advanced at a rate of 127 mm/min until puncture was achieved. Note that, 
with the ETN, the rate was reduced by half, in order to allow time for the RF energy to 
affect the tissue. The photo and diagram in Figure 3.3 were each derived using a 
Chatillon TSD110 Digital Force Tester™ (which moved the system and recorded forces). 
The tissue specimen was bonded to the holding apparatus using Loctite adhesive (Henkel 
Corporation, Westlake, OH, USA).  
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Contained within the dilator of the ETN was a 5-French electrode with a TN tip at the 
distal end, which enabled contact with the tissue. The outer diameter (OD) of the dilator 
and the inner diameter (ID) of the sheath were similar to prevent the presence of a gap at 
the interface of each.  In addition, the dilator had a tapered tip to allow for easy 
advancement across the septum, reducing the risks of tearing the FO. The dilator tip of 
the ETN was placed against the tissue to induce a mild degree of tenting. The device was 
advanced, while energy was delivered to the tip, to perform the puncture. The internal 
lumen of the dilator remained unobstructed, to allow for the needle and electrode to pass 
through the lumen and extend beyond the tip of the dilator. The amount of needle 
extension beyond the tip of the dilator was predetermined, given a restriction in the 
internal diameter of the dilator at the tip. The 5-French electrode was placed on the tip of 
a flexible Pebax® shaft (Arkema, Colombes, France) and then inserted through the inner 
lumen of the dilator. The catheters were attached using a custom fixture to a load cell for 
obtaining continuous puncture forces.  
Septal tearing  
For our septal tearing experiments, we used 86 of the swine hearts (range, 175 to 625 
grams). For each specimen, we excised the FO and surrounding tissue. Then, we 
punctured each FO with 1 of our 3 devices (a TN, an RFTN, or an ETN). Next, we 
advanced the dilator and sheath (12-, 16-, 18-, or 23-French) through the specimen.  
Once the puncture was performed, we mounted the specimen on the fixture such that no 
force was being placed against the specimen as described by Howard et al. [84] The 
delivery system was maintained in a perpendicular position relative to the FO via a  
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custom fixture. To remove any excess septal tissue, we made a cut superior to the FO,—
thereby ensuring that only FO tissue would tear during each test, while leaving the 
surrounding septal tissue unaffected. For each test, we used a TSD110 Digital Force 
Tester™ to pull the sheath away from the base, tearing through the tissue at a rate of 100 
mm/min.  The atrial septa were ripped in an inferior to superior direction. Once the 
sheath was no longer in contact with tissue, the test was terminated. We defined sheath 
tearing force as the mean force while the septum primum was tearing. We adapted our 
FO tearing method from Howard et al. [84] For our study, we recorded all FO dimensions, 
as well as mean and peak sheath tearing force.	  
Statistical	  analysis	  
Each experiment included randomized specimens of the variables, along with t tests and 
P values (set at < 0.05), to determine statistically significant differences between means. 
To examine the influence of change in variation, we normalized the puncture force data, 
using a needle type and sheath size as a reference point. To examine the relationship 
between the anatomy and puncture devices, we used analysis of variance (ANOVA) with 
a resulting R2value. For all analysis, we used Minitab version 12 (Minitab Inc., State 
College, PA, USA).  
Results	  
In our comparison of the needle subgroups, we found that sheath size affected the force to 
cross the septum and the FO’s resistance to tearing. In addition, the use of RF energy 
changed the force necessary to cross the FO. To the best of our knowledge, our study is  
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the first to show how a larger puncture device can acutely affect performance of 
transseptal punctures, sometimes doing so as well as, or even better than, more traditional 
methods (Figure 3.4).  
	  
	  
Figure 3.4: The diagram on the left (A) depicts force data (in grams) for all 
tearing and puncturing, by needle type: transseptal needle (TN), radiofrequency 
TN (RFTN), or 5-French RF electrode with the tip of a TN (ETN).  The diagram 
on the right (B) depicts force data (in grams) for all tearing and puncturing, by 
sheath size: 12-, 16-, 18-, or 23-French. 
To analyze our results, we first divided all data points into subgroups by needle type (TN, 
RFTN, and ETN); for those 3 subgroups, we calculated the mean and standard deviation 
(SD) for the dilator (TN, 299.5 ± 135.3; RFTN, 332.1 ± 107.6; and ETN, 221.1 ± 74.7 
grams), sheath size (TN, 337.8 ± 126.9; RFTN, 353.9 ± 90.2; and ETN, 272.9 ± 100.4 
grams), and tearing force (TN, 272 ± 128; RFTN, 239 ± 128; and ETN, 272 ± 151  
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grams) independent of sheath size (Figure 4A). Then, we divided all data points into  
subgroups by sheath size (12-, 16-, 18-, and 23-French); for those 4 subgroups, we 
calculated the mean and SD for the dilator (12-French, 240.4 ± 71.3; 16-French, 298.8 ± 
131.3; 18-French, 202.7 ± 102.01; and 23-French, 379.8 ± 118.9 grams) sheath size (12-
French, 413.7 ± 101.4; 16-French, 260.2 ± 125.5; 18-French,  185.4 ± 64.3; and 23-
French, 426.9 ± 132.1 grams) and tearing force (12-French, 236 ± 9; 16-French,  242 ± 
128; 18-French,  227 ± 114; and 23-French, 365 ± 173 grams) independent of needle type 
(Figure 3.4B).  
FO	  puncturing	  	  
Our study produced a total of 81 punctures from 81 specimens collected. We first 
analyzed puncture force across all sheath sizes by the 3 components (needle, dilator, 
sheath) of the delivery system (Figure 3.5A).  
Then, we calculated the mean and SD of each of our 3 devices across all sheath sizes 
(TN, 300.7 ± 163.1; RFTN, 207.6 ± 139.4; and ETN, 181.8 ± 93.5) (Figure 5B). The 
puncture force for the 2 RF-based methods (RFTN, ETN) was significantly less than for 
the TN (RFTN vs. TN, P = 0.03; ETN vs. TN, P = 0.004).  
Finally, we examined the puncture force of each paired dilator/sheath combination. In our 
analysis of all 81 specimens, we found no relationship between the dilator and sheath 
puncture force (R2 = 0.29) (Figure 3.5C).  
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Figure 3.5: The diagram on the left (A) shows, for all specimens, the mean puncture 
force and standard deviation (SD) (in grams) for the needle, dilator, and sheath by sheath 
size. The diagram on the top right (B) shows, for all specimens, the mean puncture force 
and SD (in grams) by needle type: transseptal needle (TN), radiofrequency TN (RFTN), 
or 5-French RF electrode with the tip of a TN (ETN).  The diagram on the bottom right 
(C) shows the relationship between dilator and sheath puncture forces with an overall R2 
of 0.29.      
Next, we grouped all data points by sheath size (12-, 16-, 18-, and 23-French) and then 
placed them in subgroups by needle type (TN, RFTN, and ETN) (Figure 3.6). To 
determine any significant differences in the amount of force to cross the FO, we 
compared each of our delivery systems against the 12-French system, which is used 
extensively in transseptal applications. Using the TN, we found significant differences 
between the 12- and 18-French sheath (P = 0.001) and between the 12- and 23-French 
dilator (P = 0.003). Using the RFTN, all of the sheath forces were significantly different 
from the 12-French (16-French, P = 0.003; 18-French, P = 0.001; and 23-French, P = 
0.004). Using the ETN, we found significant differences between the 12- and 18-French 
sheath (P = 0.001) and between the 12- and 23-French dilator (P = 0.05).  
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Figure 3.6: This diagram shows the mean puncture force and standard deviation 
(in grams) by needle type and sheath size. * P ≤ 0.05 
Given the specimen variation associated with inherent FO tissue properties, we 
performed an additional analysis and normalized the data to remove the specimen 
variation.  
First, we normalized the puncture methods, with the TN as the reference. By doing so, 
the mean force to cross the FO was not significantly different from the TN when using 
the RFTN (P = 0.11), but the mean force was significantly different when using the ETN 
(P = 0.01) (Figure 3.7A). 
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 Figure 3.7: The diagram on the left (A) depicts the puncture force (in grams), with data 
normalized against the transseptal needle (TN) and 12-French size, by needle type: TN, 
radiofrequency TN (RFTN), or 5-French RF electrode with the tip of a TN (ETN).  The 
diagram on the right (B) depicts the transseptal crossing force (in grams) by sheath size: 
12-, 16-, 18-, or 23-French.  
Second, we normalized sheath sizes. Using the 12-French as the reference point, we 
found that the force to cross the FO when using a 23-French sheath was significantly 
different (P = 0.005). However, we found no significant differences when using either the 
16-French (P = 0.09) or the 18-French sheath (P = 0.30) (Figure 3.7B). 
Septal	  tearing	  	  
The baseline septal tearing characteristics by needle type are summarized in Table 3.3; by 
sheath size, in Table 3.4.  The anatomic measurements of the FO, by sheath size and 
needle type, are presented in Table 3.5.  The baseline FO characteristics by needle type 
are summarized in Table 6; by sheath size, in Table 3.7. We found a statistically 
significant difference between the tearing force of the 23-French sheath as compared with  
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the 12-, 16-, or 18-French sheaths (Figure 3.5). However, needle type had no statistically 
significant impact on tearing initiation distances or on either mean or peak tearing forces 
(P > 0.05).  
Table 3.3: Baseline tearing characteristics by needle type 
 
TN (n = 26) RFTN (n = 28) ETN (n = 32) 
P 
Tearing initiation distance 
(mm) 7.5 ± 3.2 6.8 ± 3.1 5.8 ± 2.7 0.068 
Mean tearing force (gf) 272 ± 128 239 ± 128 272 ± 151 0.55 
Peak tearing force (gf) 360 ± 173 306 ± 161 372 ± 208 0.33 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the tip 
of a TN  
Table 3.4: Baseline tearing characteristics by sheath size 
 
12-French  
(n = 23) 
16-French  
(n = 23) 
18-French  
(n = 21) 
23-French  
(n = 19) 
P 
Tearing initiation distance 
(mm) 6.7 ± 2.7 6.0 ± 2.4 7.0 ± 3.7 6.4 ± 3.1 0.72 
Mean tearing force (gf) 236 ± 99 242 ± 128 227 ± 114 365 ± 173 0.002 
Peak tearing force (gf) 308 ± 138 312 ± 157 296 ± 139 515 ± 233 < 0.001 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the tip 
of a TN  
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Figure 3.8: This diagram depicts the peak septal tearing forces by sheath size: 12-, 16-, 
18-, or 23-French. The only significant difference occurred when using the 23-French 
sheath, as compared with the other 3 sizes. *P < 0.001 
Anatomic	  variation	  
 
Anatomy	  for	  puncture	  	  
The variation in anatomy among our specimens affected both the FO puncturing process 
and the septal tearing forces.  
FO	  puncturing	  	  
Overall, we found only a narrow variation in the FO thickness of our specimens (0.46 ± 
0.07 mm). We found no statistically significant relationship between FO thickness and 
the type of device used (R2 for TN, 0.001; ETN, 0.005; and RFTN, 0.11) (Figure 3.9).  
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Figure 3.9: This 3-part diagram depicts the relationship between FO thickness (in 
mm) and puncture force (in grams) using (A) the transseptal needle (TN); (B) the 
5-French radiofrequency electrode with the tip of a TN (ETN); and (C) the RFTN. 
In addition, we analyzed the relationships between sheath size (12-, 16-, 18-, or 23-French) and 
FO anatomic measurement by needle type, but found no statistically significant differences 
(Table 3.5).  
Table 3.5: Anatomic measurements of the fossa ovalis  
 
12-French TN RFTN ETN P 
SI length (mm) 13.5 ± 2.8 11.6 ± 3.7 15.7 ± 4.1 0.56 
AP length (mm) 7.2 ± 2.6 7.8 ± 2.4 7.07 ± 2.05 0.89 
Thickness (mm) 0.39 ± 0.3 0.5 ± 0.1 0.32 ± 0.1 0.14 
 
16-French    
 
SI length (mm) 12.9 ±3.5 15.3 ± 2.9 13.7 ± 4.6 0.47 
AP length (mm) 8.6 ±4.9 7.1 ± 5.3 7.7 ± 2.2 0.89 
Thickness (mm) 0.5 ±0.1 0.6 ± 0.3 0.5 ± 0.1 0.75 
18-French    
 
SI length (mm) 15.3 ± 3.3 14.5 ± 4.4 13.9 ± 2.1 0.87 
AP length (mm) 8.3 ± 3.4 7.9 ± 2.6 8.3 ± 2 0.94 
Thickness (mm) 0.4 ± 0.1 0.6 ± 0.3 0.3 ± 0.1 0.11 
23-French    
 
SI width (mm) 12.4 ± 4.5 13.5 ± 1.3 17.0 ± 7.1 0.45 
AP width (mm) 6.9 ± 3.3 8.2 ± 1.8 10.1 ± 5.6 0.42 
	  
	  
Thickness (mm) 0.4 ± 0.1 0.4 ± 0.1 0.29 ± 0.26 0.25 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the tip 
of a TN; SI = superior/inferior length; AP = anterior/posterior length  
 
Septal	  tearing	  
We collected anatomic measurements for all of the specimens used for tearing, to 
determine any relationship between anatomy and tearing resistance, but found none.  
Table 3.6: Baseline fossa ovalis characteristics by needle type 
 
TN (n = 26) RFTN (n = 28) ETN (n = 32) 
P 
SI length (mm) 11.8 ± 2.3 14.4 ± 4.5 13.2 ± 2.5 0.01 
AP length (mm) 5.8 ± 2.2 8.6 ± 4.5 7.8 ± 2.0 < 0.001 
Thickness (mm) 0.8 ± 0.5 0.9 ± 0.7 0.9 ± 0.3 0.58 
Heart weight (grams) 387 ± 81 415 ± 110 376 ± 74 0.22 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the tip 
of a TN; SI = superior/inferior length; AP = anterior/posterior length  
Table 3.7: Baseline fossa ovalis characteristics by sheath size 
 
12-French 
 (n = 23) 
16-French 
 (n = 23) 
18-French  
(n = 21) 
23-French 
 (n = 19) 
P 
SI length (mm) 13.3 ± 3.2 12.6 ± 2.7 12.7 ± 3.6 14.2 ± 3.6 0.37 
AP length (mm) 7.7 ± 3.6 7.3 ± 3.0 7.3 ± 2.2 7.8 ± 3.0 0.92 
Thickness (mm) 0.8 ± 0.4 1.0 ± 0.6 0.9 ± 0.5 0.8 ± 0.5 0.49 
Heart weight (grams) 379 ± 109 408 ± 80 391 ± 89 389 ± 79 0.75 
TN = transseptal needle; RFTN = radiofrequency TN; ETN = 5-French RF electrode with the tip 
of a TN; SI = superior/inferior length; AP = anterior/posterior length  
 
We found a statistically significant difference between when each method of puncture 
was compared against the (SI) length (P = 0.01) the (AP) length (P < 0.001) (Table 3.6). 
But we found no other statistically significant differences. Although samples were 
randomized, there was a significant difference between anterior/poster and 
superior/inferior width for the needle groups (P <0.05) 
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Discussion	  
Our study was the first of its kind to assess the forces required to perform a transseptal 
puncture through the FO. Our 4 main findings were as follows: (1) In the case of 16- and 
23-French sheath systems, the force required to cross the FO is higher than for a 12-
French system; (2) When comparing our 3 types of devices, the ETN significantly 
differed from the TN, but the RFTN did not; (3) With the 23-French sheath size, the FO’s 
tearing resistance was significantly higher than the other sizes; and (4) Between the 12-, 
16-, and 18-French sheath sizes, the FO’s resistance to tearing did not significantly differ.  
FO	  puncturing	  
When comparing the TN with the RFTN, the TN resulted in lower transseptal crossing 
forces of the dilator and sheath with the smaller 12- and 16-French systems, and the 
RFTN resulted in lower transseptal crossing forces with the 18- and 23-French systems. 
The use of the larger ETN resulted in lower mean transseptal crossing forces with the 12-, 
16-, and 18-French systems. It is possible that the RF lesion created by the ETN enabled 
the dilator and sheath to cross with greater ease, as we also observed with the RFTN.  
The dimensions of the dilators and sheaths might contribute to differences in forces by 
delivery system size. The variation in forces by delivery system size and by needle type 
might be due to the unique design of each dilator. Additional work is necessary to 
optimize dilator tip design.  Our data (normalized against the 12-French system) showed 
no significant differences in mean puncture forces with the 16- and 18-French systems. 
The lack of differences in normalized mean puncture forces may be due to design 
elements such as tip contour or tolerance differences between each component of the  
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delivery system.  
Furthermore, when comparing all needle types by sheath size, FO thickness had no 
significant impact.  However, the difference in FO thickness with the ETN subgroup was 
significantly smaller than with the other 2 devices (P < 0.05).  Our additional analysis 
comparing FO thickness and puncture force (grams) revealed, with all 3 needle types, the 
lack of a strong correlation between FO thickness and puncture force.  Thus, the variable 
of FO thickness might have been a confounding factor.  In future studies, a broader 
selection of same-size devices is warranted, in order to explore the variation from device 
to device within a particular size.  
It is important to note that during transseptal punctures with the 5-French electrode 
needle (i.e., with the ETN), we observed, in some specimens, steam pops when using a 
power setting of 30 watts. The use of RF energy might cause the tissue temperature to 
increase, resulting in dielectric breakdown and vaporization of the fluid, damage to the 
adjacent tissue, and release of the contents as a steam pop. In our observed cases, the 
amount of power applied exceeded the amount required to cause rupture and resulted in 
fluid vaporization near the tip of the catheter. With the optimization of applied power and 
temperature settings, it might be possible to control the energy delivery and eliminate this 
phenomenon; the literature suggests that tuning ablation parameters can minimize steam 
pop occurrences. [83]  
These results indicate that additional studies of a larger RF-based device might yield 
improvements in reducing the amount of force required to perform transseptal punctures.  
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The lack of a significant difference between the normalized mean puncture force of the 
TN and RFTN might be associated with the amount of power delivered or with 
insufficient time exposure of the tissue subject to the RF (given the effects of the 
mechanical force of the needle against the tissue). Anatomic variation of FO size and 
thickness might contribute to the variation in the forces for FO puncturing and septal 
tearing. Using the TN as a baseline, we found that either the ETN or RFTN led to 
comparable or better results—evidence that all 3 devices perform similarly. A chronic 
study is required with several months of follow-up to examine the post-procedure 
recovery of the FO and to investigate the post-procedure healing of punctures performed 
by both mechanical and RF methods. 
Septal	  tearing	  	  
We observed significant differences in septal tearing properties by sheath size; our results 
correspond with previous investigations. [84] It appears that a critical sheath diameter 
exists at which tearing forces dramatically increase (Figure 3.8). As new procedures 
continue the trend toward larger catheter sizes to reduce septal tearing, the initial 
puncture holes created are still of concern. Yet, the clinical implications of iatrogenic 
atrial septal defects remain to be clinically determined. It is important to note that some 
physicians are already using closure devices to treat these defects.  
Regardless of the needle type (TN, RFTN, or ETN), we found no statistically significant 
differences in the tearing forces with the 12-, 16-, and 18-French systems. This finding 
suggests that, on an acute scale, no single technology has demonstrated a clear reduction 
in iatrogenic atrial septal defect size. Someday, technologies may facilitate tissue  
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remodeling resulting in better closure. Future investigations are needed to determine 
whether or not transseptal punctures aided by RF will generate better natural closure in 
the long term.  
Additional work is needed to better understand the ETN and to account for variations in 
anatomic differences. Opportunities also abound to further investigate different iterations 
of the ETN that may perform better than the one we used. 
Study	  limitations 
In our analyses of the septal tearing tests, we assumed that the surrounding anatomy of 
the FO had little impact on the observed forces. Depending on the pertinent anatomy 
targeted in the procedure, catheter torquing might be amplified, resulting in changes in 
tearing forces. An in vivo study or a biomechanical model examining this behavior would 
aid in identifying the importance of other factors relative to septal tearing.  
In addition, our study focused on transseptal elements at the time of puncture. Additional 
work is needed to study the residual hole that is formed, including a safety study to 
examine FO healing.  
Although our study found no statistically significant difference by needle type and FO 
thickness, additional work is needed to study the interactions between device size and 
anatomic variation in FO thickness and size.  
Finally, the ability to perform similar studies on fresh tissue isolated from human hearts 
would be ideal; such studies are ongoing in our laboratory, but it will take time to acquire  
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the necessary specimens. 
Conclusion	  
Ours is the first study to characterize how the currently accepted TN compares with the RFTN	  and	  ETN. Using a range of devices and catheter sizes, we successfully showed the 
relative puncture and tearing forces required to perform transseptal punctures and FO 
tearing. Normalized mean puncture forces using the TN and RFTN were not different.  
Additional studies aimed at reducing septal puncturing and tearing forces are needed, 
optimizing designs by refining not only the shapes and sizes of delivery systems but also 
the power used. Solutions must be found to improve the safety of transseptal punctures.  
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Preface	  
The inspiration for this study arose as a result of the review chapter.  Limitations in the 
ability to place catheters in specific locations pose a therapeutic and patient safety risk.  
Insufficient contact and orientation of the therapeutic catheter can result in insufficient 
lesion depth that could result in extended procedure times or a redo of the ablation at a 
future date.  Devising new techniques based on direct visualization of the device tissue 
interface provides insights into the procedure to illustrate how to effectively apply 
ablation devices.  The results of this study will be submitted to Heart Rhythm Journal. 
For this study, I was responsible for study design, conducting the data collection, image 
analysis, and publication creation. Both Boaz Avitall and Paul Iaizzo provided editorial 
support.  In addition, Boaz Avitall conducted catheter navigation during the procedure to 
ensure the devices were used in a way to mimic clinical procedure.   
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Introduction	  
Post-ablation reoccurrences of atrial fibrillation (AF) continues to be a concern in the 
treatment of patients. [85, 86]  Therefore, several adjuvant procedures have been promoted 
to improve overall outcomes.  One of these, the ablation of the mitral isthmus (MI) has 
emerged in an attempt to decrease the likelihood of macro-reentrant tachycardia. [87, 88, 89, 
90, 91]  Nevertheless, the creation of a transmural MI block for the treatment of AF is often 
quite difficult to achieve as good catheter placement, stability and tissue contact are 
challenging due to a given patient’s anatomy. [87] Incomplete lesion sets may lead to a 
slow conduction path that could result in left atrial tachycardia. [92, 93, 94, 95]  
In this report we have employed direct imaging modalities within a reanimated human 
heart during the placement of a catheter against the MI as a means to provide novel 
educational tools for physicians, design engineers, and/or patients: i.e., to better 
understand the specific limitations of the current procedure and suggested procedural 
changes that can lead to improve linear lesion generation.   
Experimental	  Setup	  
A human heart was reanimated in a clear Krebs-henseleit buffer using Visible Heart® 
methodologies and endoscopic footage during an ablation procedure was obtained. [96, 97] 
This heart was considered nonviable for transplantation (recovered via LifeSource, St. 
Paul, MN): we also used numerous reanimated swine heart studies to validate these 
ablative approaches.  The catheters were advanced through the inferior vena cava (IVC), 
across the fossa ovalis (FO), to the anatomical location of the LA MI.  A Contactr 8mm 
radiofrequency catheter (Medtronic, Inc., Minneapolis, MN, USA) was advanced through  
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a transseptal sheath to the desired position against the MI.  The catheter ablation was 
conducted per the manufacturer’s recommended settings using temperature mode at 65 
degrees of a period of a total time of 17 minutes and then removed.   
Shown in Figure 4.1, the catheter tip was placed next to annulus of the mitral valve 
(MV). A second diagnostic catheter is inserted through a sheath and placed such that the 
interior of the deflection point of the ablation catheter rested on the shaft of the diagnostic 
catheter.  The tip of the diagnostic catheter is logged in the PV to anchor the diagnostic 
catheter and restrict the movement of the ablation catheter.  The ablation energy was 
turned on and a lesion was created as the catheter was dragged toward the ostium of the 
pulmonary veins (PV), which are located in the center of the screen below the ablation 
catheter shaft (Figure 4.1A). As the ablation catheter was pulled along the ridge, the 
ablated tissue appeared to become dimpled and changed in color (Figure 4.1B). 
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Figure 4.1:  Mitral isthmus linear lesion was created in a reanimated human heart: (A) 
shown in the initiation of linear lesion with support from transseptal sheath and 
secondary diagnostic catheter; (B) the ablation catheter –1– is pulled along MI with 
twisting of diagnostic catheter -2- towards FO and retraction of transseptal sheath – 3 – 
from LA; (C) shown is an increased deflection of ablation catheter – 4 – and increased 
twisting of diagnostic catheter – 5.  The uses of both the transseptal sheath and a support 
catheter was advantageous to maintain contact on the MI. LA – left atrium, MI – mitral 
isthmus, MV – Mitral valve, PV – pulmonary vein 
 
 
The catheter was then advanced over a ridge in the LA.  To generate good contact, 
abundant deflection of the ablation catheter tip was required and the delivery sheath was 
also utilized for added support. (Video Appendix A) Yet, during the course of the 
ablation, the delivery sheath was retracted into the RA to better allow for the ablation 
catheter tip to maintain contact as it was pulled across the MI (Figure 4.1C). Persistent 
contact between the ablation catheter and diagnostic catheter were required in order to 
maintain tip orientation and prevent the ablation tip from sliding along the tissue.  (Figure 
4.1B)  Finally, the support of the diagnostic catheter prevented the ablation catheter from 
changing orientation to its side. During the course of being able to visualize such ablation 
procedures, we observed that there may often be a procedural need for a high number of 
deflections of the given ablation catheter; i.e., in some cases a MI ablation may require a 
90-120 degree deflection of the delivery sheath at its distal tip, so to achieve placement of 
the ablation catheter in the desired location (see supplemental video – Appendix A).   
Upon completion of the human heart, this procedure was validated in a swine model to 
examine the effectiveness of the technique using a post procedure lesion assessment. 
Swine post-procedural evaluations included the use of triphenyl tetrazolium chloride (TTC):  
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i.e., each sample was placed in a TTC bath for 20 minutes to allow for the creation of 
color differentiation, health versus dead tissue: ablated tissue appears blanched and non-
ablated tissue was deep purple. (Figure 4.2) 
 
 
Figure 4.2:  Shown are several views of sectioned and TTC stained left atrial samples: 
(A) the ablated atrial tissue appear as blanched; (B) shown is the PV inverted and the MI 
line is circled; and (C) cross-section view of linear mitral isthmus lesion, depicting 
transmurality. 
	  
Via the staining, the presence of the ablated region became quite visible (Figure 4.2A).  
The pulmonary vein and atrial tissue was then inverted to further examine the full extent 
of the linear lesion which extended form the MV annulus to the PV ostium (Figure 4.2B).  
Finally, the lesion was sliced to examine lesion transmurality (Figure 2C).  These results 
show that the ability to generate a successful lesion in this MI anatomy is influenced by 
maintaining tip orientation and high tissue contact.  In this case, these were influenced  
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by, the support of a delivery sheath that was retracted into the RA during the ablation, 
and a secondary support catheter was also used to provide support to the ablation 
catheter.   
Discussion	  
This clinical approach shown here is an innovative way to utilize currently available 
ablation tools as a means to increase the success rate of achieving a transmural lesion of 
the MI.  Studies showing that conduction block at the MI can be challenging, reinforce 
the need for advanced ways to treat such patients.[98]  The presence of the ridge that may 
boarder between the MVA and the PV can be a very challenging anatomy, due to their 
varied shapes and sizes.  The orientation of the sheath and the proximity of the MVA can 
result in the catheter ablation electrode laying on its side against the tissue.  (Figure 4.3B)  
This orientation limits the amount of force that can be placed on the tissue by the ablation 
catheter as the catheter will slide along the tissue as more contact force is placed against 
it.  Also, as the catheter tip is moved over the ridge, the tip can lose contact, on the ridge, 
making it a challenge to ablate all the tissue on both sides of the ridge.  (Figure 4.3A) 
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Figure 4.3:  Shown is the movement of the catheter using a traditional approach A) 
catheter tip movement (green arrow) over the ridge (blue dash) B) catheter tip drag (green 
arrow) starting a MI in the direction of the ridge (blue dash).   
 
This is considered to contribute to an often inability to maintain tissue contact that is 
sufficient to generate transmural lesions.  (see supplemental video – Appendix B) In 
addition, the relative location of the MI relative to the FO prevents the delivery of a long 
section of steerable sheaths and/or catheters into the LA: i.e., often reducing the relative 
amount of contact the catheter shaft can have on the MI.  It has been noted that 
innovative approaches are often needed that allow for better forces to be transferred from 
the ablation catheter tip along endocardial tissue: such capabilities would in turn allow 
for greater contact forces resulting in more consistent transmural lesion.     This present 
study utilized Visible Heart methodologies as a novel means to observe the device-tissue 
interface during the combined approach of catheters and sheaths to augment ablation 
outcomes, these insights may help clinicians in their desire to enhance clinical outcomes  
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for transmural MI lesion generations.   
Conclusion	  
The unique in vitro imaging employed here of reanimated hearts, aided to better 
understand the challenges of catheter navigation as it relates to movement, placement, 
orientation, and stability within the left atrium during MI ablation procedures.  This direct 
visualizations approach was useful to explore additional variables such as catheter tip 
angles, power delivery, and ablation durations as a means to modify clinical approaches 
to achieve appropriate catheter placements for ultimately eliciting proper lesion 
formations.  
Appendix	  A	  
Supplementary data 
RF	  -­‐ 	  Mitral	  isthmus	  -­‐ 	  human.wmv  
Appendix	  B	  
Supplementary data 
RF	  -­‐ 	  traditional	  approach.wmv
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Key	  teaching	  points	  
• Support provided by secondary diagnostic catheters may aid to increase the stability 
of the ablation tip of therapeutic catheter, which in turn will result in improved 
endocardial contact and a transmural linear lesion of the MI. 
• The creation of the linear lesion requires the movement of the various parts of the employed 
system: including the ablation catheter, support catheters, and/or transseptal sheath. 
• In some human anatomies, the therapeutic catheter and/or the delivery sheath may require a 
degree of retraction into the RA, i.e., in order to maintain contact on the MI as the ablation tip 
approaches the relative location of the transseptal puncture. 
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Preface	  
This chapter is inspired from the learnings of the previous chapter and the first chapter.   
Atrial fibrillation (AF) is an arrhythmia where the atrial chambers of the heart contract 
chaotically and inefficiently. One method of treating AF is to ablate areas within the heart 
that are causing the irregular stimulation. Ablation can be performed with various types 
of energy. Currently, radio-frequency is the most common energy. 
The mitral isthmus is an anatomy of the left atrium that is commonly targeted during 
ablation therapy. The mitral isthmus is roughly characterized by a line from the left 
inferior pulmonary vein down to the mitral valve and can be ablated via a catheter in the 
coronary sinus. Therefore, an understanding of the relative anatomies of the coronary 
sinus and mitral isthmus is useful for the design of coronary sinus ablation catheters. 
The motivation of this study is to characterize the coronary sinus relevant to mitral 
isthmus ablation. Specifically, we assessed the coronary sinus ostium anatomy, the 
distance along the coronary sinus from the ostium to the mitral isthmus, and the anatomy 
of the coronary sinus at the mitral isthmus. We have compared these parameters between 
specimens with a history of atrial fibrillation and specimens with no history of cardiac 
disease. We assessed these parameters using magnetic resonance (MR) 101 imaging of 
30 perfusion fixed hearts (15 with atrial fibrillation and 12 control). The MR imaging 
method was consistent with the previous study.  The results of this work include 
intellectual property creation that is owned by Medtronic.   
This study was a group effort with myself, Julianne Spencer, Ryan Goff, and Steve  
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Howard. As a group, we decided on the parameters to be measured that would provide 
the most useful information in the development of coronary sinus ablation catheters. 
Julianne was responsible for the imaging of the specimens, the development of the 
measurement protocol using Mimics reconstruction software, and a portion of the data 
and statistical analysis. Steve Howard contributed his atrial fibrillation knowledge by 
assisting us in locating the mitral isthmus and general feedback throughout the project.  
Ryan Goff also provided helpful feedback throughout the duration of the project. I was 
responsible for the study design, compilation of the manuscript, and a portion of the data 
analysis.  Cassandra Sundaram and Maria Seewald assisted in the collection of data 
measurements from the MR scans.  This work is part of a completed manuscript 
submission to a Journal of Arrythmia. 
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Summary	  
Background:	  	  	  
Linear ablation of the mitral isthmus (MI) of the left atrium (LA) is a common procedure 
for patients suffering from atrial fibrillation (AF). Yet, detailed assessments of 
dimensional anatomic data that might influence the application of ablation therapy are 
seldom reported.  In this study, we assessed variations in cardiac anatomy (the tissue 
thickness, the presence of fat, and other dimensional data) that might correlate with the 
effects of catheter ablations. 
Methods:	  	  
In our laboratory, 30 donated human hearts underwent perfusion fixation and subsequent 
magnetic resonance imaging (MRI). Through this novel means, we aimed to perform 
detailed assessments of the coronary sinus (CS) and the MI—both of which are common 
target sites for catheter ablations in the treatment of AF.  We divided the heart specimens 
into 2 groups: non-AF, from donors without AF (mean age, 52 ± 19 years) and AF, from 
donors with AF (mean age, 72 ± 11 years).  We focused on CS vasculature anatomy and 
MI morphology adjacent to the CS.   
Results:	  	  
On average, the distances along the coronary sinus to the CS mitral isthmus plane were 
50.4 ± 14.1 mm in the non-AF group and 66.8 ± 14.6 mm in the AF group (P < 0.01). 
The CS vasculatures were 3.4 ± 1.3 mm away from the LA MI in the non-AF group and 
5.6 ± 2.0 mm away in the AF group (P < 0.01). The CS ostial circumferences were 31.2 ± 
10.7 mm in the non-AF group and 35.2 ± 15.3 mm in the AF group (P = 0.63). The CS 
circumferences at positions of the MI were 21.3 ± 7.8 mm in the non-AF group and 18.1  
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± 4.1 mm in the AF group (P = 0.09).  
Conclusions:	  	  
Our study of perfusion-fixed human heart specimens helped identify unique anatomic 
variations that might influence application of radiofrequency (RF) ablation energies for 
transmural lesions.  We found that elicitation of fat adjacent to the CS, reduction in the 
relative size of the CS, and increased distance from the CS to the LA endocardial surfaces 
in the MI planes might all contribute to the possibility, after treatment, of incomplete 
transmural lesions, thereby preventing complete MI conduction block.  
 
Keywords: Atrial fibrillation, catheter ablation, magnetic resonance imaging, mitral 
isthmus, coronary sinus 
 
Abbreviation List: AF = atrial fibrillation, CS = coronary sinus, LA = left atrium, MI = 
mitral isthmus, MRI = magnetic resonance imaging  
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Introduction	  
The application of ablation therapy within the coronary sinus (CS) and the mitral isthmus 
(MI) of the left atrium (LA) has been shown to effectively treat persistent atrial 
fibrillation (AF) [99]. The creation of a linear lesion at the MI is a common practice—and a 
challenge to complete while attempting to achieve electrical isolation [100,101]. Ineffective 
ablation applications within this region have been reported to be pro-arrhythmic [102]. 
When properly performed, ablations of the CS and MI are able to create a linear set of 
lesions that terminate conduction pathways in patients with persistent AF [103,104,105,106]. 
 
In order to carry out effective ablation therapy within the CS and MI, physicians must be 
able to navigate through a highly variable region of cardiac anatomy [100,107,108]. Wong et 
al. [102] characterized the regional anatomy (Figure 5.1). The creation of a lesion is based 
on the catheter tip placement from within the CS and is affected by the distance from the 
CS to the MI, the CS circumference, the tissue thickness, and the presence of fat in the 
region of the MI.   
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Figure 5.1:  Schematic diagram of the cross-section along the mitral isthmus (MI) from 
the mitral valve annulus to the left inferior pulmonary vein (LIPV). The blue vessel 
represents the coronary sinus (CS); the red vessel, the left circumflex artery. 1 indicates 
the long and thick MI; 2, the recess/pouch/crevice; 3, the muscular sleeve around the CS; 
4, convective cooling by blood flow in the CS and the artery; 5, the 0° position of the CS 
circumference. 
 
A detailed understanding of the anatomic structures of the CS and MI, and their 
relationships to the adjoining anatomy, is critical [100, 101]. Previous studies have used 
computed tomography (CT) images to characterize the morphology and anatomy in this 
region during the course of ablation therapy [99,102]. Several of them additionally 
investigated the endocardial surface shape of the MI; however, they did not characterize 
the anatomy at the plane of the MI from within the CS to the MI [100, 102].  Some recent 
studies suggested that older patients (ages 68 to 93 years) might not undergo any age- 
105 
	  
	  
based LA size change [103]. The specimens in our study encompassed a broad age range, 
 so we were able to distinguish changes in anatomy based on the presence or absence of 
AF.   
 
The use of catheters in both the CS and along the MI contributes to the creation of 
transmural lesions.  Previous work has shown that effective catheter orientation can result 
in lesion depths of 6.3 to 6.5 mm and that lesion depth is negatively affected by poor 
catheter tip orientation or by low contact force [109, 110].  Therefore, knowing the tissue 
thickness and composition provides insights that might contribute to the effectiveness of 
lesion creation.   
 
The purpose of our study was to characterize CS vasculature anatomy, and MI 
morphology adjacent to the CS, that might affect the ability to effectively use RF ablation 
catheters when creating transmural lesions. The potential variations in this regional 
anatomy are clinically important, particularly for patients with persistent AF. 
Methods	  	  
In our laboratory, 30 donated human hearts underwent perfusion fixation and subsequent 
magnetic resonance imaging (MRI), with 3-dimensional reconstruction of the MI and CS 
anatomy to measure the desired anatomy.  Through this novel means, we aimed to 
perform detailed assessments of the CS and the MI—both of which are common target 
sites for catheter ablations in patients with AF.  We divided the heart specimens into 2 
groups: the non-AF group (control specimens from donors without AF) and the AF group  
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(specimens from donors with AF).  We focused on CS vasculature anatomy and MI 
morphology adjacent to the CS.  To determine any significant differences in cardiac 
anatomy, we conducted a statistical analysis.   
MRI	  with	  Anatomic	  Reconstructions	  and	  Measurements	  
The heart specimens were perfusion-fixed with a head pressure of approximately 50 mm 
Hg with 10% formalin, as previously described [110]. This step allowed the specimens to 
maintain a pseudo end-diastolic shape and thus remain in a more realistic anatomic form.  
The specimens were then embedded in a 7% agar solution to decrease MRI artifacts [110]. 
Scans of the 30 specimens were obtained with a 3T scanner (Magnetom TRIO 3T MRI 
scanner, Siemens Corp., Munich, Germany), using a magnetization-prepared rapid-
acquisition gradient-echo ( MP-RAGE) (T1-weighted) protocol with a base resolution of 
512. We chose MRI because of its ability to clearly quantify high spatial and temporal 
resolution measures of cardiovascular structure and to distinguish myocardial tissue from 
fat [111,112,113].  
CS	  vasculature	  anatomy	  
We devised a set of anatomic measurements deemed to affect the ability to use a 7-
French  ablation catheter.  After combining the MRI images to render a 3-dimensional 
dataset reconstruction, we analyzed it using Mimics Software (Materialise, Leuven, 
Belgium). The set of CS measurements included CS diameters and circumferences, 
distances along the CS from its ostium to the MI, and the cross-sectional shape at the MI.   
 
We imported each of the cardiac image sets and combined them into 3-dimensional  
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reconstructions of the LA and the CS.  The LA reconstruction was used to define the CS 
center line, determined by taking the 2-dimensional cross-section of the CS and finding 
the center point of the CS (Figure 5.2).  The center point was used as an origination 
reference point to determine degree positions on points of the CS circumference at the MI 
plane.  The MI plane was defined as the shortest distance from the CS center line to the 
LA endocardial surface 
 
Figure 5.2: Anatomic reconstruction of the left atrium (LA), coronary sinus (CS), and 
left inferior pulmonary vein (LIPV). The yellow mitral isthmus (MI) plane line intersects 
the CS center line as measured in the reconstructed 3-dimensional model.  The light blue 
line depicts the CS center line.   
 
inferior to the left inferior pulmonary vein (LIPV) and superior to the mitral valve 
annulus (Figure 5.2).  After determining the MI plane, we re-sliced the scans so that the 
cross-section of the CS was at the MI plane. In that plane, we assessed the long and short 
axis diameters, circumferences, and shapes of the CS.  
MI	  morphology	  
To further analyze MI anatomy affecting catheter usage, we examined the distance to the 
LA, the presence of fat in the region subject to ablation energy, and the distances at  
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degree positions on points of the CS circumference.    We identified the location of fat by 
the variation in contrast seen within the MRI images, then verified the location by 
sectioning the heart into slices (3 to 5 mm thick) after fixation (Figure 5.3). The slices 
were subjected to MRI, in order to verify  
 
 
Figure 5.3: A magnetic resonance imaging (MRI) image (left) and a photograph of the 
same human heart specimen (right). The left atrium (LA) endocardial space is labeled 
(left atrium). The specimen section includes the coronary sinus (CS); immediately 
inferior to it is a deposit of fat that is visible on both the MRI image and the photograph. 
 
that the gray scale of the fat around the CS in the initial MRI images correlated to the fat 
seen on the slices. 
Using a 2-dimensional MRI slice at the plane of the intersection of the CS center line and 
the MI line, we drew a line across the mitral annulus as a reference. Next, we drew a line 
parallel to the mitral annulus across the center of the CS cross-section and defined that 
line as 0°. Finally, we created 3 additional lines through the center of the CS cross- 
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section at 45°, 90°, and 135° to the 0° line (Figure 5.4). We assessed the presence of fat  
 
Figure 5.4:  Analysis of the coronary sinus (CS) at the mitral isthmus (MI). The 0º to 
180º line is parallel to the mitral annulus. Using the CS center line, we created degree 
positions around the CS (0º, 90º, and 180º), in order to measure distances to the 
endocardial MI.  The left atrium (LA) and left ventricle (LV) are labeled for reference. 
between the intersection of those lines with the boundary of the CS and the LA as a 
binary parameter. Then, we measured the distance from the CS to the LA space at each 
position around the CS. 
Statistical	  analysis	  
Data are presented as the mean ± standard deviation. To compare 2 related samples, we 
used a nonparametric Wilcoxon rank sum test (α = 0.05) to determine any statistically 
significant differences between the AF group and the non-AF group (Table 5.1). The 
dependent samples are not assumed to be normally distributed, resulting in the use of the 
Wilcoxon rank sum test.  The AF group was older and had a larger male: female ratio, 
but had similar body weights relative to the non-AF group.  We included the non-AF  
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control group to account for variation introduced by the perfusion fixation process.   
Results	  
Study	  specimens	  
The 30 perfusion-fixed human hearts used in our study were considered nonviable for 
transplantation via both LifeSource (St. Paul, MN) and the bequest donation program at 
the University of Minnesota (Minneapolis, MN). The AF group included 15 specimens; 
so did the non-AF control group, which included heart specimens from donors without 
AF or any other clinical cardiac diagnoses (Table 5.1). 
 
Table 5.1: Donor characteristics (n = 30) (mean ± standard deviation) 
  
Non-AF group  
(n = 15) 
AF group (n = 
15) P (α  = 0.05)  
Age at death (years) 52 ± 19 72 ± 11 0.01* 
Gender (male: female) 4:11 9:6 N/A 
Weight (kg) 76.8 ± 21.8 81.2 ± 24.8 0.65 
* a significant difference (P < 0.05) 
AF = atrial fibrillation; N/A = not applicable 
CS	  vasculature	  anatomy	  	  
For all 30 heart specimens, we assessed CS anatomy against anatomic dimensions that 
might affect the ability to deliver and use a focal ablation catheter.  CS ostial plane 
measurements of circumference, long axis, and short axis (35.2+-15.3 mm, 12.3 +-6.9 
mm, and 7.3+-3.0 mm) were not significantly different, P>.05 between the 2 groups.  Nor 
were 2 of the CS measurements at the MI plane: CS circumference and CS short axis; 
however (18.1+-4.1 mm, 4.5+-1.4 mm)  were not significantly different (P=.09 and .97) .  
However, CS long axis (6.4+-1.7 mm) was significantly different (P=.03) when  
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compared against non-AF hearts.  (Table #5.2)  
Table 5.2: CS anatomic measurements, mm (n = 30) 
  
Non-AF group 
(n = 15) 
AF group 
(n = 15) 
P (α  = 
0.05) 
    
CS ostial plane     
CS circumference 31.2 ± 10.7  35.2 ± 15.3  0.63 
CS long axis 11.2 ± 4.1 12.3 ± 6.9 0.92 
CS short axis 6.8 ± 2.6 7.3 ± 3.0 0.69 
CS at MI plane    
CS circumference 21.3 ± 7.8 18.1 ± 4.1 0.09 
CS long axis 8.1 ± 3.1 6.4 ± 1.7 0.03* 
CS short axis 4.7 ± 2.0 4.5 ± 1.4 0.97 
* a significant difference (P < 0.05) 
AF = atrial fibrillation; CS = coronary sinus; LA = left atrium; MI = mitral 
isthmus 
 
Per CS measurements at the MI plane, CS circumference decreased by 48.5% in the AF 
group and by 31.8% in the non-AF group.  Note that a traditional ablation catheter has a 
diameter of 2.33 mm (7-French). In the AF group, the higher reduction in circumference, 
along with the smaller CS long axis and smaller CS short axis, reduced the ability to 
apply deflection at the catheter tip.  Hence, in the AF group, the ability to achieve contact 
with the wall of the CS was impaired.  In addition, the size of the CS continued to be 
larger than the catheter, resulting in intermittent contact in the CS at the MI plane.   
MI	  morphology	   
The distance from the ostium to the MI plane along the CS in AF and non-AF patients 
(66.88+-14.6 mm, 50.4+-14.1 mm) were significantly different, p=.01. (Table 5.3). So 
did the distance from the CS to the LA at the MI plane. 
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Table 5.3: MI anatomic measurements, mm (n = 30) 
  
Non-AF group 
(n = 15) 
AF group 
(n = 15) 
P (α  = 
0.05) 
    
Distance from ostium to MI plane 
along CS 
 50.4 ± 14.1 66.8 ± 14.6 < 0.01* 
CS at MI plane    
      Distance from CS to LA at MI 
plane 3.4 ± 1.3  5.6 ±2.0  < 0.01* 
* a significant difference (P < 0.05) 
AF = atrial fibrillation; CS = coronary sinus; LA = left atrium; MI = mitral 
isthmus 
 
In the AF group, the overall presence of fat was higher at every point of the CS 
circumference except the 270° position; the difference was significant at the 90° position 
(P = 0.03) and the 315° position (P = 0.01).  
	  
	  
 
Figure 5.5: Presence of fat and distance to mitral isthmus (MI) at the position of the 
coronary sinus (CS) at the MI plane, in degrees around the CS: red, atrial fibrillation (AF) 
group; blue, non-AF group.  (A) Distance around the CS at the MI plane to the left atrium 
(LA) space, in mm.   (B) Bar chart comparing the percentage of hearts where fat was 
present, next to different positions on the CS.  The shortest label (–) compares the 0° AF 
position with the shortest (15°) non-AF position. 
 
The smallest percentage of fat in the AF group was at the 0° position; the shortest 
distance to the LA in the AF group was at the 0° and 45° positions (Figure 5.5).  
 
In total, we observed fat in 79 (59%) of 135 positions in the non-AF group and in 109  
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(81%) of 135 positions in the AF group (data not shown). Moreover, the average distance 
from the CS to the LA space was greater in the AF group at every position assessed 
around the CS. The differences between the 2 groups were significant at 2 positions: 0° 
(P < 0.01) and 315°  (P = 0.02).  
Discussion	  
Major	  findings	  
According to our study of 30 heart specimens, CS anatomy, MI morphology, and minor 
position differences on the circumference of the CS at the MI plane might all influence 
the effectiveness of catheter ablation therapy—specifically, the ability to achieve good 
contact with the desired tip placement, resulting in transmural lesions.  Given the inherent 
limitations in the penetration of a lesion, anatomic changes and differences might limit 
the ability to create transmural lesions.   
CS	  vasculature	  anatomy	  
We found that CS circumference at the MI plane exceeded that of a traditional ablation 
electrode.  In addition, CS circumference was not large enough to allow the catheter tip to 
be placed perpendicular to the tissue. In the region of the MI, the CS short axis diameter 
(4.7 ± 2.0 mm) in the AF group was larger than the commonly available 7-French (2.3 
mm) ablation catheter tip.  This constraint resulted in the catheter tip lying against the 
wall of the CS or in a slight amount of deflection at the tip: in either situation, the amount 
of contact force that can be placed on the catheter tip was low. Wong et al. [101] found that 
when CS diameters at the MI were larger than the catheter tip, the catheter tip needed to 
be manipulated many times in order to achieve tissue contact. The relatively large  
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average diameter in our study (short axis: 4.7 ± 2.0 mm in the AF group) suggests that, in 
human patients, placing the catheter tip on the desired tissue and thus achieving 
successful ablation will be challenging.  This inability to achieve sufficient contact might 
be a primary reason for the low success rates, clinically, in the creation of transmural 
lesions.   
MI	  morphology	  	  
From the perspective of the tip of the ablation catheter, we found that MI morphology, 
along with adjacent anatomic changes with the onset of AF, complicated the ability to 
create transmural lesions.  
 In the AF group, the shortest distance to the MI was at the 45° position (5.8 ± 2.0 mm). 
However, at the 0° position, we observed the lowest percentage of fat (60%), as well as 
the second shortest distance (6.0 ± 2.0 mm) to the endocardial MI. Moving 45° in an 
inferior direction to the 315° position, we saw an increase in the distance to the LA and a 
higher percentage of fat.  Thus, catheter tip placement between the 0° and 45° position 
might be more desirable than between the 0° and 315° position.  Using the anatomical 
measurements from this study along with additional studies that examine both the 45 and 
315 degree position to quantify the amount of fat present would aid in refining the 
ablation produce to achieve a transmural lesion.  
At every degree position around the CS, the distance between the CS and the LA space 
was longer in the AF group than in the non-AF group.  
Previous work by Yokokawa et al. [99] demonstrated that changes in the ablation settings 
might be required to achieve transmural lesions. They examined characteristics of the  
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anatomy in this same anatomic region that we did, focusing on the orientation of the 
circumflex artery, the curvature of the MI, and additional CS measurements at the MI.  
They, too, found that effective catheter placement was critical in the creation of 
transmural lesions and pinpointed anatomic elements that can contribute to ineffective 
catheter usage.  Our study further refines their conclusions by suggesting that the 
preferred anatomic positions for catheter tip placement are at the 45°, 0°, and then 315° 
position at the plane of the MI within the CS.   At the 90° and 270° position, we 
documented a sharp increase in both the distance to the LA and the presence of fat.   In 
addition, the tissue thickness increased between the CS and the LA in the region of the 
MI in the AF group (3.4±1.31mm for non-AF hearts versus 5.6 ± 1.97 mm for AF 
hearts).   
 
Clearly, our findings reinforce the need for modifications to ablation settings.   
The changes in anatomy that we observed between non-AF and AF hearts, along with the 
changes in MI morphology, all support the notion that ablation durations and settings 
need to be modified, in order to result in transmural lesions. The use of traditional 
anatomic landmarks around the MI aids in positioning ablation catheter tips within the 
CS, but might be insufficient for achieving effective lesions necessary for electrical 
isolation [100]. 
We also found that defining the CS center line facilitated the ability to find the MI plane 
within the CS that is the shortest distance. Using the CS center line as a reference, we  
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were able to obtain measurements that affected creation of transmural lesions.   The 
presence of fat in the region of the MI plane, along with changes in distance from the CS 
to the MI, might contribute to less than ideal creation of lesions. 
Study	  limitations	  
Our study was limited by the effects of the perfusion fixation process that can result in an 
approximate 10% reduction in overall heart size.  Our non-AF control group was used to 
account for changes introduced through the fixation process, but fresh specimens would 
have removed the need for a control group.  
Conclusions	  
Transmural lesion creation is affected by catheter contact force and lesion depth.  CS 
vasculature anatomy and MI morphology in the region of the LA might contribute to 
limiting the effectiveness of RF ablation aimed at creation of transmural lesions.  The 
slightly longer CS distances in the AF group suggest that LA volumes are predictably 
larger [100,102].  
 
In addition, the presence of fat adjacent to the CS might prevent creation of effective 
linear lesions.  The clear differences in the tissue thickness of the MI in the AF group 
show that variation in the tissue thickness might be beyond the penetration depth of a 
lesion.  An effective path for a transmural lesion might be achieved by orienting a 
catheter tip that is not in the plane of the mitral annulus away from that plane, at about a 
45° angle, from within the CS.   
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Finally, CS circumferences indicate that the ability to affix a catheter in the distal areas of 
the CS might require specific manipulations to ensure that the catheter tip is in contact 
with atrial tissue.  The ability to apply greater contact force at the catheter tip allows for 
more precise tip placement and improved lesion creation.  This ability would be an 
improvement to catheter design, increasing the chance of lesion creation on viable tissue 
and thus improving the efficacy of linear ablation of the MI. 
Conducting these measurements in the CS at the MI plane reveals the shortest path to 
create a lesion, as well as the anatomic limits of lesion penetration.  
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Preface	  
The inspiration for this study arose from the development of a catheter device used for 
the collection of monophasic action potentials and the observed limitations to control 
catheter placement as observed in chapters 1 and 4.  Monophasic action potentials (MAP) 
have been demonstrated as a method to depict cardiac depolarization that is able to be 
collected through the use of an intracardiac catheter.  These signals can be collected when 
physical pressure is placed against the tissue causing the waveform to pass underneath 
the catheter tip as the tissue depolarizes.  Recently, research has shown the ability to 
collect MAPs.  However, there have been limitations in that it is unknown what is the 
appropriate amount of pressure to apply to the tissue the generate MAPs.  Insufficient and 
excessive pressure both result in no MAP signal.  Recent studies using contact force in 
the creation of radiofrequency lesions have demonstrated that insufficient pressure results 
in a poor lesion and excessive pressure results in risk of cardiac tamponade.   
The ability to understand the contact force to generate a MAP would show what the 
necessary pressure is to collect a MAP and prove the ability to show if the tissue at the tip 
of a catheter is electrically viable.  Future studies in this area could bring together the 
contact force for both ablation and MAPs as a way to help direct ablation therapy to the 
areas that are electric ally conductive at the tip of the catheter. The key to be able to 
accomplish this is to know if there is sufficient pressure at the location of interest that 
should result in the ability to collect a MAP. 
 
For this study, I was responsible for making the devices, calibration, study design, 
conducting the data collection, data analysis, and publication creation. A biomedical  
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engineering student, Megan Schmidt, and staff scientist, Tinen Iles, assisted in the 
majority of data collection and data analysis. The contents of this chapter were submitted 
as a manuscript to the Journal of Cardiovascular Electrophysiology.    
Summary	  
Background:	  	  	  
In this study of catheter use in swine hearts, our objective was to examine in vivo contact 
force (CF) and its possible correlation with epicardial or endocardial cardiac monophasic 
action potentials (MAPs).   
Methods:	  	  
MAPs were generated from swine hearts both in situ (after a medial sternotomy) and in 
vitro from hearts reanimated using Visible Heart® methodologies.  
Results:	  	  
We collected and analyzed a total of 99 endocardial points and 380 epicardial points.  At 
each site, for all points, we determined the mean CF and the CF standard deviation (SD).  
The mean CF required to generate MAPs for all 9 pigs was 9.54 ± 2.43 grams.   The 
mean CF widely varied among hearts.  Of note, the mean CF for 2 of the hearts (11.47 
grams) was significantly higher than for all of the other hearts (5.05 grams) (P < 0.0001).  
Conclusion:	  	  	  
In this study of catheter use in swine hearts, we successfully showed the relative CF 
required to generate MAPs in various regional anatomies, both epicardially and 
endocardially.  The mean CF required to generate MAPs was different across locations 
in/on the heart and varied from heart to heart.   
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Keywords: Atrial fibrillation, catheter ablation, mitral isthmus, coronary sinus 
Abbreviation List 
AF = atrial fibrillation, CF = contact force, CS = coronary sinus, ECG = 
electrocardiography, EOR = end of repolarization, LA = left atrium, LV = left ventricle, 
MAPs = monophasic action potentials, MI = mitral isthmus, OF = outflow tract, PV = 
pulmonary vein, RA = right atrium, RF = radiofrequency, RV = right ventricle, SD = 
standard deviation, TAPs = transmembrane action potentials  
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Introduction	  
Clinically, focal signals of monophasic action potentials (MAPs) are collected when 
localized cardiac excitation repolarizations are desired; a reason is to supplement the data 
obtained from complex fractionated atrial electrograms.  These MAPs can indicate what 
is occurring electrically in regional anatomies in situations when conventional bipolar or 
unipolar electrograms are unable to accurately do so.  In the past several decades, devices 
have been developed to collect MAPs in real time, but with varying degrees of success. 
Furthermore, generating MAPs requires an applied contact force (CF) of the catheter onto 
the heart to depolarize the tissue.  The limited success of these devices might be linked to 
an inappropriate amount of CF with the tissue.  Additionally, anatomic location might 
affect the amount of CF required to generate MAPs. 
 
Specifically, MAPs are recorded waveforms or signals that focally characterize electrical 
excitations (depolarizations and repolarizations) of the myocardium.  Synchronized to 
cardiac function, MAPs are able to show localized signals describing activation timing, 
density, pattern, and velocity.  Today, it is common to use gross electrograms that depict 
electrical potentials across larger regional anatomies; however, electrograms are often 
convoluted and distorted by far-field signals and double counting.[114,115,116,117]  The use of 
MAPs allows for a more physiological focused study of cardiac substrate by collecting 
very localized repolarization activity. [118,119]  Recording their high-fidelity signals 
enables clinicians to classify activation of tissue regions and to then use that information 
for subsequent ablation decisions, instead of relying on broad-based and incomplete  
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electrogram data. [120]  
The use of MAPs to direct the care of human patients and to better understand their 
cardiac function has been reported in studies exploring transmembrane action potentials 
(TAPs), atrial flutter, and ablation therapy for patients with atrial flutter.  In 1986, Franz 
and Burkhoff et al. [121] conducted pioneering experimental research on MAP recordings, 
using novel devices.  In perfused rabbit septum preparations, they recorded contact-
electrode MAPs simultaneously with TAPs; then, they quantitatively compared those 2 
signals for duration and area at 30%, 60%, and 90% repolarization.  Their data indicated 
that using novel devices to collect MAPs helped accurately measure the repolarization 
time course of TAPs.   
In 2009, in a porcine model, Aidonidis and Poyatzi [122] hypothesized that the patterns of 
local repolarization in the high and low right atrium (RA) would allow determination of 
the site with pronounced propensity to map disorganization during atrial flutter and atrial 
fibrillation (AF).  They used focal catheters that were capable of continuously generating 
MAPs.  The high atrial MAPs revealed discordant repolarization during atrial flutter or 
AF, whereas the low atrial MAPs maintained their baseline regular morphology.  In their 
study, the focal catheter was used only in the RA.  Subsequently, other investigators 
began using such catheters within the left atrium (LA) where AF rotors are most often 
described. [120,121,122,123]  
Thus, in human patients, generating MAPs is considered a useful means to precisely 
depict the localized depolarizations and repolarizations of clusters of myocardial cells 
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[124,125].  In addition, other investigators have shown the utility of swine studies for 
observing and better identifying MAPs.[126,127]  Clinically, gathering these signals might 
be the best way to identify the substrates on which AF patterns form or are sustained. 
[128,129]  Early identification and treatment of such sites may aid in understanding the 
emergence of AF. 
The need to apply a degree of physical pressure (i.e., CF) to generate MAPs raises this 
key question: Just how much CF is required, using a typical catheter, and should it vary 
relative to the anatomic site in/on the heart? [119,121]  Studies similar to ours have looked at 
CF as it relates to the application of cardiac mapping and ablation. [130,131,132] In our study, 
in order to address any correlation of CF with MAPs, we employed several 
methodologies.  First, we collected epicardial MAPs in situ from swine hearts after a 
medial sternotomy and the creation of a pericardial cradle.  Second, using previously 
described Visible Heart® methodologies [133,134] to reanimate swine hearts, we generated 
both epicardial and endocardial MAPs in vitro in various regional anatomies (e.g., the 
mitral valve annulus, the right ventricle outflow tract [RVOT], and septum).  Third, 
knowing that radiofrequency (RF) ablation has used CF to aid in creating lesions and that 
a number of studies have quantified the CF required to generate lesions with a range of 
results [131,136,137] ,  we quantified the CF to generate a MAP.  The dual objectives of our 
study were to (1) determine the amount of CF required to generate MAPs using a 
catheter-based approach and (2) investigate how the amount of CF required to generate 
MAPs varies in different anatomic locations. 
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Methods	  
Study	  population	  
Nine animals were subject to mapping.  These studies were performed using Yorkshire 
Cross pigs that were initially anesthetized with 500 mg of Telazol and 500 mg of 
methohexital, and then intubated for general anesthesia (maintenance with ~ 1.5% 
isoflurane, > 2 minimal alveolar concentration).  Each pig was continuously monitored 
using electrocardiographic (ECG) recordings as well as left and right ventricular pressure 
measurements.  Our study was reviewed and approved in accordance with the University 
of Minnesota Animal Care and Use Committee.   
Mapping	  procedure	  
All pigs underwent either epicardial or endocardial mapping.  We collected simultaneous 
CF and MAP epicardial signals from the RV and left ventricle (LV) apex, from 5 
locations on the RV septum, and from the RVOT (Figure 6.1).  Endocardial locations 
included the RVOT, RV anterior free wall, RV apex, RV septum, Right atrial appendage 
(RAA) opening, tricuspid annulus, coronary sinus (CS) ostium, anterior papillary muscle, 
and RA superior free wall.   
 
 
 
 
 
126 
	  
	  
 
Figure 6.1:  Epicardial sites for CF/MAP signals collection. RVOT = right ventricular 
outflow tract, RV = right ventricle, LV = left ventricle RAA = right atrial appendage, CS 
= coronary sinus, RA = right atrium  
 
Simultaneously, we collected heart rate from a number of sources, including 
electrograms, exposed electrodes on the surface of the catheter, and a roving diagnostic 
ECG catheter.     
For epicardial point collection, we performed a medial sternotomy in each pig, and 
stabilized the heart by forming a pericardial cradle.  To collect epicardial MAPs, we 
placed the catheter (Figure 6.2) in a holding apparatus, thereby allowing for precise control 
of its tip’s placement and orientation against the epicardial surface. 
For endocardial point collection, we used a separate set of anatomic locations.  After our 
in situ experiments, we performed a standard cardioplegia procedure, then excised the  
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heart for our in vitro studies.   In the jugular vein of each pig, we placed a 12.5 French 
introducer to provide endocardial access.  To directly visualize the interface between the 
endocardial device and the tissue, we used Visible Heart® methodologies, as previously 
described. [133]. We placed the excised porcine heart on the apparatus and reanimated it, 
using a clear Krebs-Henseleit buffer.  Only specimens that elicited normal cardiac 
function (e.g., a native sinus rhythm) were analyzed.   
 
Figure 6.2:  (A) Design of the tip of the MAP catheter (4) with 4 distal electrodes 
(2) and 2 – 2 mm band electrodes (5) that are mounted on the shaft of the catheter.  
The tip electrodes are isolated from each other using a polymer (1, 3); the catheter 
is able to collect both unipolar and bipolar signals. (B) Illustrates the catheter tip 
as it engages the tissue surface.  The electrodes and fiber Bragg grating strain 
sensor (orange tube) come in contact with the tissue at the same time.  Contact is 
denoted by deformation of the fiber grating in the right panel of (B).  This 
deformation is translated into grams of CF. CF = contact force, MAP = 
monophasic action potential 
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Depolarization was defined by the maximal slope of the upstroke of the MAP recording. 
Local end of repolarization (EOR) was defined as the intersection between the baseline 
and the tangent to the steepest slope on phase 3 of the MAP (Figure 6.3).  
 
Figure 6.3:  MAP depolarization and repolarization. During phase 0 
(depolarization), sodium enters the cell; during phase 2, calcium enters the cell 
and contraction starts; during phase 3 (repolarization), potassium exits the cell. 
MAP = monophasic action potential 
 
  
We used comparative beat-to-beat measurements in case of MAP distortions or any 
disturbance to the baseline due to respiratory or cardiac contractions.  Activation time 
(AT) was defined as the time interval from the earliest recorded ventricular activation to 
local activation, the; EOR time, as the time interval from the earliest ventricular 
activation to local EOR; and MAP duration, (MAPDUR) as the time interval from local 
activation to local EOR. (Figure 6.4A) Values were obtained at each site, taking the 
peaks of a QRS complexes time references. (Figure 6.4B)To account for affect associated 
with respiration and cardiac movement, we measured the CF for a MAP after observing a  
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series of 4 consecutive MAPs.    
To amplify and digitally record all MAP signals from each electrode, we used a 
computer-based laboratory system (PowerLab, ADInstruments, Colorado Springs, CO).  
Each MAP signal was recorded in a bipolar configuration, i.e., between tip electrodes and a 
2-mm ring electrode.  We also obtained a unipolar electrogram, with a filter bandwidth of 
0.1 to 120 Hz.   Increasing force was applied to the location until the first MAP signal was 
generated.  (Figure 6.4C)  We used the CF at the time of the last set of 4 consecutive MAP 
signals to examine any affect associated with tissue deformation due to sustained force from 
catheter placement.  Additionally, for those anatomies that were affected by respiration, we 
implemented a momentary breath hold for a period of 10 to 30 seconds, in order to reduce 
the impact of any effects associated with respiration; on completion of a breath hold, the pig 
was allowed time to recover and to resume natural respiration. 
                          
 
Figure 6.4:  (A) Signals that served to define AT, APD, and RT.  (B) A single 
MAP (purple) and ECG (black) signal captured on the RV epicardium.  (C)  
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Catheter orientation, direction of motion, and orientation for epicardial 
measurements. APD = action potential duration, AT = sum of activation time, 
ECG = electrocardiography, MAP = monophasic action potential, RT = 
repolarization time, RV = right ventricle 
In addition to collecting MAPs, we placed a 5 French bipolar electrode, either epicardially 
or endocardially, to simultaneously collect far-field signals.  
Contact	  force	  measurement	  	  
To measure CF, we used a system consisting of a treatment/recording electrode tip with 4 
separate conductive mapping electrodes (Figure 6.2A) and an additional lumen that 
contained a fiber Bragg grating (Figure 6.2B). [135]  A diffraction grating, the fiber Bragg 
grating was built into the optical fiber; it reflected light at a very specific wavelength. The 
wavelength related to the strain applied to the fiber. An optical interrogator (HBM, 
Germany) was employed as a "swept wavelength" laser to determine the reflected 
wavelength, which then represented the relative strain.  Each was constructed in short 
segments of optical fiber with an accuracy of ± 1 nm.  Strain was assumed with Bragg 
displacement in relation to a reference length, and was transformed into a normalized 
measure of deformation, i.e., the relative amount of strain that was generated was 
computed as a general deformation.  Each fiber Bragg grating strain sensor was calibrated 
before the start of data collection.  The tip of the fiber had a measureable force (grams) 
placed against it.  The force was incrementally increased and at each increment the 
frequency and force were collected.  This resulted in a frequency to force relationship 
that was used to derive a linear expression that was the calibration curve.    This 
calibration process enabled each unique piece of fiber to be normalized to grams.   
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Statistical	  analysis	  
Each experiment included basic statistical analyses including randomized samplings of 
the variables along with t tests to determine any significant differences between means.  
Because we took multiple measurements from a single specimen, we used Levene’s test 
to assess the equality of the variation across all specimens.  A significance level of 0.05 
was used for global test statistics and for Levene’s test. To examine the influence of 
change in variation, we normalized the CF data using the epicardial mediolateral RV as a 
reference point.  For all statistical analyses, we used Minitab version 12.  We conducted a 
power analysis between MAP generation and CF, as compared with the observed CF 
used for generation of ablation lesions, in order to assess the number of observations that 
would be required to find a significant difference between those CFs.   
Results	  
	  
Our study’s results demonstrate that contact alone is not enough to generate MAPs; 
rather, a certain threshold of force must first be achieved.  Because of that activation 
threshold, investigators have been unable to discern, at least with current catheter-based 
methods of collecting data on MAPs, whether or not the contact force from the catheter 
was sufficient for generating MAPs.  But with the device method we used in our study, 
we were able to demonstrate, for the first time, the amount of force required to repeatedly 
generate high-quality MAPs.  In addition, we showed that our catheter method was 
capable of collecting data by placing the tip at slight angles that were not perpendicular, 
in variable positions, without leading to any significant differences in generating MAPs.   
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Epicardial	  and	  endocardial	  mapping	  
Mapping of all endocardial and epicardial sites were performed only on hearts 
contracting in a normal sinus rhythm.  Epicardial MAPs were recorded in situ while 
endocardial MAPs were collected in vitro from re-animated swine hearts. We collected 
and analyzed a total of 99 endocardial points and 380 epicardial points. To maintain 
consistency among all points, we oriented the catheter to be perpendicular to both the 
endocardial and epicardial surface (Figure 6.5).   
 
Figure 6.5:  (A) The catheter contained within the delivery sheath/fixture was 
oriented to be perpendicular to the epicardial surface of the right ventricle (RV).  
(B) The catheter’s electrode tip and fiber Bragg grating were near the endocardial 
surface in the right atrium on the Visible Heart® apparatus.    
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Figure 6.6: Catheter tissue CF (including the mean and SD) is depicted at all endocardial 
and epicardial mapping points.  Color bars indicate 100% of measurements by anatomic 
location; the percentage breakdowns, bands of CF (grams); gray bars, the mean and SD at 
each anatomic point.  At the far right, the number of points by anatomic location is 
indicated in either an epicardial (Epi) or endocardial (Endo) grouping. CF = contact 
force, RVOT = right ventricular outflow tract, RV = right ventricle, LV = left ventricle 
RAA = right atrial appendage, CS = coronary sinus, RA = right atrium, gm = grams 
   
The mean CF to generate MAPs for all 9 pigs was 9.54 ± 2.43.  Given the large variation 
in CF between anatomic locations, we performed Levene’s test, resulting in an overall 
equal population variation across all hearts (P = 0.969).  CF was lowest at the 
mediolateral RV septum locations (7.56 ± 4.36) and highest at the RA free wall (15.68 ±  
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0.936) (Figures 6.6).  The CF required to generate MAPs was significantly higher (P < 
0.0001) in the RA in the RA free wall (15.68 ± 0.936) and the superior free wall (15.01 ± 
0.505), as compared with the overall mean.   
Across all anatomic locations, CF ranged from 1.05 to 22.67 grams.  Of the total of 470 
points, we observed low CF (1 to 5 grams) at 157 points (32.8%); modest CF (5 to 10 
grams) at 128 points (26.81%); moderate CF (10 to 15 grams) at 176 points (36.51%); 
and high CF (15 to 20 grams) at 18 points (3.7%) (Figure 6.6). 
Epicardial	  RV	  mapping	  
We measured 7 anatomic locations in situ, for a total of 380 points from 7 hearts.  All 
data, expressed as the CF required to collect the first 4 consecutive MAP signals, were 
broadly distributed (Figure 6.7A).   The mean CF for the mediolateral RV septum 
locations (Figure 6.7B) did not differ significantly. But the mean CF for the RV septum 
locations (7.56 ± 4.36, Figure 6B and for the RV and LV apex (8.7 ± 4.81, Figure 6.7B), 
nearly differed significantly (P = 0.08).   The mean CF for the RV apex (8.5 ± 4.98) and 
for the LV apex (8.89 ± 4.63) did not differ significantly (P = 0.56).   
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Figure 6.7:  (A) We collected all of these points, in 7 anatomic locations.  (B) We 
organized the 7 anatomic locations by CF color bands. (C) The blue dot is the mean CF, 
the grey dots are each observation.  CF = contact force, RV = right ventricle, LV = left 
ventricle RA = right atrium, gm = grams 
	  
We defined the point of first contact as the first set of 4 consecutive MAPs.  To refer to 
the points where all 4 electrodes were in contact with the tissue, we used the phrase “all 
on.” When the catheter was removed from a location, the CF for the last 4 consecutive 
MAPs was also taken.  The mean CF for all epicardial anatomic points from the first 4 
consecutive MAPs (7.56 ± 4.36 grams) and for “all on”   engagement (10.83 ± 2.29 
grams) differed significantly (P < 0.0001). However, for those same epicardial anatomic  
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points, the mean CF from the first 4 consecutive MAPs (again, 7.56 ± 4.36 grams) and  
for the last 4 consecutive MAPs (8.67 ± 5.32) did not differ significantly (P = 0.10) 
(Figure 6.8).  
	  
Figure 6.8: Each line represents an individual swine heart (n = 7).  The “first 4” point 
indicates the mean contact force (CF) required to generate 4 consecutive monophasic 
action potentials (MAPs) across all epicardial anatomic points;  the “all on” point, the 
mean CF when the catheter tip is fully engaged in the tissue; and the “last 4” point, the 
last 4 consecutive MAPs.  
The CF for the first 4 consecutive MAPs was significantly lower than for the entire 
catheter tip (all on) (P < 0.0001).  The application of the catheter in a given anatomic 
location resulted in tissue deformation from the CF of the catheter tip on the tissue.  Yet 
the deformation did not result in a significant difference between the CF required to 
generate the first 4 and the last 4 consecutive MAPs (P = 0.111).   
Endocardial	  mapping	  
Having successfully obtained MAPs employing the epicardial approach, we collected 
data at endocardial points, under direct visualization, using Visible Heart®  
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methodologies.  To ensure proper catheter placement, we made slight changes in tip  
location.  Some investigators have speculated that placing the catheter in the same 
location enables the same set of cells to be in contact with the catheter electrode.  Our 
ability to do so was eased by the absence of respiratory movements and by the large 
reduction in cardiac contraction based movement.   
Placing the catheter in the same location contributed to the smaller SD in 5 endocardial 
locations (0.037, 0.058, 0.057, 0.041, 0.03) (Figures 6.9A and 6.9B).  The highest mean 
CF required to generate MAPs was for the RA superior free wall (15.68 ± .93) and for the 
RV anterior free wall (15.01 ± 0.5).   
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Figure 6.9:  (A) a total of 9 anatomic locations showing the distribution of CF at each 
location.  (B)  9 anatomic locations by CF color bands. (C) The mean is shown by blue 
dot,  all observations are grey dots within 3 bands for all points.  CF = contact force, 
RVOT = right ventricular outflow tract, RV = right ventricle, LV = left ventricle RAA = 
right atrial appendage, CS = coronary sinus, RA = right atrium. gm = grams 
According to Levene’s test, the variation was equal for all 4 hearts (P = 1.00).   The equal 
variation was due, in part, to the absence of any respiratory influences and to the 
reduction in cardiac movements, since these hearts were functioning in vitro.   
Variation	  from	  heart	  to	  heart	  
In our study, CF depended not only on the anatomic location but also on the individual 
heart (Figure 6.10).  We observed wide variation in the mean CF from heart to heart. Of 
note, the mean CF for hearts 6 and 7 (11.47 grams) was significantly different than for 
hearts 1, 2, 3, 4, and 5 (5.05 grams) (P < 0.0001).  
Figure 6.10:  CF differences at each epicardial point collection location.  (A) CF is 
shown at the right ventricular outflow tract (RVOT), right ventricular apex (RV apex), 
and the left ventricular apex (LV Apex) 3 epicardial points.  (B) CF is shown at 4 
epicardial septum locations of the RV septum. RVOT = right ventricular outflow tract, 
RV = right ventricle 
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It is possible that differences related to the makeup of the tissue stiffness may contribute 
to the heart to heart variation.  Additional trials are needed to understand further the 
extent of variation from heart to heart.  
Anatomic	  point	  variation	  
CF exhibited large variation about the mean, so we normalized the data, using an 
epicardial reference, in order to reduce the variation associated with the specimen.	  	  We 
used in situ measurements of 7 anatomic locations with the mediolateral RV septum 4 as 
the reference point.  The normalized CF did not differ significantly from the CF for the 
mediolateral RV septum locations (2, P = 0.139; 3, P = 0.227; 5, P = 0.815) and for the 2 
inferior locations (6, P = 0.088; 7, P = 0.397) (Figure 6.11). But the normalized CF 
differed significantly from the CF for the RVOT (P = 0.004).   
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Figure 6.11:  (A) 9 endocardial locations by whether CF was significantly (blue) or 
nonsignificantly (purple) different from the normalized epicardial reference (yellow).  (B) 
7 epicardial locations by whether CF was significantly (blue) or nonsignificantly (purple) 
different from the normalized epicardial reference (yellow) CF = contact force, RVOT = 
right ventricular outflow tract, RV = right ventricle, LV = left ventricle RAA = right 
atrial appendage, CS = coronary sinus, RA = right atrium 
To examine the relationship between the epicardial reference point and the endocardial 
locations, we performed an additional normalization to a single epicardial location.  
Using the mediolateral RV septum 4 as the reference point, we measured 9 anatomic 
locations.  The normalized CF was significantly different from the CF for all 9 
endocardial locations: RVOT (P = 0.038), RV anterior free wall (P = 0.0001, apex (P =  
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0.0001), RV septum (P = 0.048), RA ostium (P = 0.0441), tricuspid annulus (P = 
0.0394), CS ostium (P = 0.0489), anterior papillary muscle, and RA superior free wall (P 
= 0.0001).   
Discussion	  
In our study, we illustrated several key points: (1) the CF required to generate MAPs 
varied widely; (2) small changes in anatomic location did not result in significant 
differences in the CF; (3) large changes in epicardial location did result in significant 
differences in the CF; (4) the mean CF across hearts often differed significantly; and (5) 
the mean CF to generate MAPs differed significantly from the mean (20 grams) 
commonly used to generate an endocardial RF lesion.   
Recently, numerous studies have examined CF as it relates to generating RF lesions in 
various anatomic locations.  According to those studies, the CF required to generate 
ablation lesions ranges between 9 and 40 grams. [131, 136, 137]  In our study, we observed 
mean CFs  to generate a MAP were lower than CFs suggested to generate effective  RF 
lesions.[131, 138, 139]  Effective RF lesion creation can be accomplished with a range of CF 
and these studies suggest that 20 grams of CF may be a very effective amount of force.  
The differences between suggested CF of these studies compared to the CFs from this 
study may suggest that the force needed to generate MAPs may be different than those 
used for ablation.  We also used a novel catheter to simultaneously record both CF 
(grams) and MAPs.  Those measurements proved useful in determining any differences 
in the CF required in different anatomic locations.  The ability to combine ablation and  
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MAP CF may prove to be an effective tool to improve the overall ablation procedure.  To 
the best of our knowledge, ours is the first systematic study to examine in vivo CF as it 
relates to generating MAPs.   
 Our novel data indicate that it is possible to describe the CF to record MAPs epicardially 
or endocardially. During our study, we did not have an instance of perforating the heart 
as we were applying CF. In addition, we observed a threshold of CF where the signals 
would change in morphology (Figure 6.12).  As the catheter CF decreased, the shape of 
the signal changed: the tissue did not have the necessary depolarization from the catheter 
to enable us to measure the changes in boundary current and thus record MAPs. 
 
Figure 6.12:  The signal on the left had sufficient CF (contact force). The change in the 
signal as the catheter was removed is depicted on the right: that CF was insufficient to 
generate monophasic action potentials (MAPs).  
Future work is needed to collect additional data from human hearts, in order to better 
understand that these signals change and that they have implications for repolarization.   
In our study, we noted that the required CF varied with the anatomic site being  
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investigated.  The sensor method that we used was very effective for a catheter-based 
approach and provided a nearly instantaneous response to changes in CF.  When 
recording MAPs clinically, one needs to consider the effects of cardiac and respiratory 
movements along with challenges of catheter placement on the anatomy.  In our study, 
we accounted for such effects by using a series of 4 consecutive MAP signals (first and 
last) to define successful contact.  Doing so prevented the use of premature signals that 
could have been induced by cardiac or respiratory movements.  Yet even greater data 
fidelity might be achieved by computational models that can eliminate the effects of 
cardiac and respiratory movements. A future study focusing on developing an adaptive 
model to compensate for respiratory and cardiac movement to isolate the genesis of the 
first MAP signal could more precisely describe the CF required. In addition, improving 
the catheter design to allow it to be used is varying tip orientations may extend the 
usefulness of the device. 
The ability to characterize the amount of CF to properly detect and record MAPs has 
important clinical applications, e.g., relative to understanding how to ensure that ablation 
lesions are effective within an anatomic region.  It may be possible to use the presence of 
a MAP as an indicator that the minimum CF needed for RF lesion creation has been 
satisfied.   Therefore, serving as an indicator to determine when to apply ablation therapy.   
Additional work needs to be done to integrate this technology with an ablative capability, 
so that MAPs can be measured and ablated in the same location.   
Our use of the fiber Bragg grating was a highly effective way to augment the operation of  
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the catheter and to measure CF in a large number of different anatomic locations.  
However we did observe that the fiber Bragg grating sometimes broke at the tip.  In order 
to prevent a compromise in operation, we used 8 different fibers across the 9 swine 
hearts.  Each grating was calibrated, and linear expressions derived, in order to convert 
frequency into grams. Each linear expression between nanometer frequency and grams 
had an observed R-sq. of between 0.98 and 0.995 over a range of .2 to 20 grams.  The 
fiber Bragg grating was most accurate when it was perpendicular to the tissue surface.  
For all of our endocardial measurements, we used direct visualization in the Visible 
Heart® to validate catheter tip orientation before signal collection.   
To evaluate the relative importance of an orthogonal catheter orientation, we collected a total of 
24 points that focused on catheter orientation (Figure 6.13).  First, in the mediolateral RV septum, 
we tried a perpendicular orientation, resulting in mean CF of 12.21 ± 5.62.  Placing a 20-degree 
inferior tilt on the catheter resulted in a mean CF of 10.07 ± 6.29.  A 20-degree superior tilt 
resulted in a mean CF of 10 ± 6.56.  But those differences were not significantly different (P = 
0.33).  
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Figure 6.13: Changing the catheter tip orientation and position changed the contact force 
(CF) at the same anatomic epicardial location.   
Thus, if the catheter was not in an orthogonal orientation, the relative variation in the 
amount of CF required to generate MAPs varied, on average, by 20%.  
Study	  limitations	  
We need to mention several limitations unique to the methods we used.  First, the fiber 
Bragg grating was mounted to the catheter shaft, resulting in both strong sensitivity and  
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exposure that, at times, caused the grating to break when placed against anatomic 
structures.  Second, each piece of grating had a unique frequency, resulting in the need to 
calibrate each grating.  A consistent frequency for every grating might have resulted in 
better data consistency. Third, the adjustment of cardiac and respiratory movements 
could be improved by considering a device that compensates for anatomic movements, 
potentially leading to a higher resolution of the CF.    
Conclusion	  
In this study of catheter use in swine hearts, we successfully showed the relative CF 
required to generate MAPs in various regional anatomies, both epicardially and 
endocardially.  The mean CF required to generate MAPs was different across locations 
in/on the heart and varied from heart to heart.  The mean CF required to generate MAPs 
was significantly lower than the mean CF required to generate an endocardial RF lesion. 
Yet, further studies are needed to improve the fidelity and capabilities of force integration 
with ablation procedures.   
These novel insights should help both clinicians and catheter designers who need 
procedural requirements to generate reproducible MAPs from various locations in either 
the endocardium or on the epicardial surface of a beating heart.  The ability to accurately 
record these underlying myocardial potentials could provide critical information during 
ablation procedures. MAPs can provide insight into local heterogeneities to allow 
targeting of ablative and biologic therapies.  
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Preface	  
The inspiration for this study arose from the development of a catheter device used for 
the collection of monophasic action potentials as part of the previous chapter.  
Monophasic action potentials (MAP) have been demonstrated as a method to depict 
cardiac depolarization that is able to be collected through the use of an intracardiac 
catheter.  These signals can be collected when physical pressure is placed against the 
tissue causing the waveform to pass underneath the catheter tip as the tissue depolarizes.  
The previous chapter proved a method to collect MAPs and the necessary contact force to 
generate them in various anatomic locations.   
This technical brief is designed to apply this device design to bring together the contact 
force and MAPs as a way to help direct ablation therapy to the areas that are electrically 
conductive at the tip of the catheter. If the tissue at the tip of the catheter is electrically 
conductive, then these locations may be those where additional ablation is needed. 
For this study, I was responsible for making the devices, calibration, study design, 
conducting the data collection, data analysis, and publication creation. A biomedical 
engineering student, Megan Schmidt, assisted in data collection. The contents of this 
chapter were submitted as a manuscript to IEEE Engineering in Medicine and Biology.   
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Summary	  
The use of therapeutic ablations in patients with atrial fibrillation has become mainstay in 
the treatment of this disease.  Yet, often such individuals require multiple procedures: in 
other words, successful first time treatments are impacted by challenges in generating 
linear lesions in specific anatomical regions like the mitral isthmus of the left atrium.  
Hence, there is a need to find reliable assessment techniques to address the presence of 
conduction gaps at the time of lesion creation.  In this study, we describe a novel 
approach to examine conduction gaps, i.e., by using a proof of concept device to examine 
the local activation in the area of the lesion to locate gaps in the lesion set.  Both 
epicardial and endocardial linear ablation lines composed of focal lesions with 
conduction gaps were created in a porcine model.  Investigations of epicardial placed 
linear lesions applied on the right ventricle, including a conduction gap, were performed 
while recording monophasic action potentials (MAPs).  Endocardial ablations were 
performed on the left atrial mitral isthmus.  
 We were able to successfully demonstrate the use of a proof of concept MAPs 
catheter with the ability to find a conduct gap within a linear lesion set: in those instances 
where no signals were collected, the device was able to collect the amount of applied 
force in both epicardial and endocardial locations. This device could be employed 
clinically with a novel catheter design, so to better assess lesion quality: i.e., importantly 
identify the existence of a conduction gap.  
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Introduction	  
Today, mitral isthmus (MI) ablations are conducted in a given patient in an attempt to 
decrease the likelihood of reoccurrence of atrial fibrillation. [140,141]  Yet, anatomic 
challenges may often have an unintended consequences in performing these procedures, 
with even the possibilities of generating proarrhythmic outcomes. [140,141]  Additionally, 
creations of incomplete MI lesions may lead to a slow conduction pathway that could 
ultimately result in left atrial tachycardia. [142,143,144,145]   Yet, the occurrences of post-
ablative conduction gaps in such procedures have also been associated with limitations of 
currently available catheter ablation devices. [146,147,148]  In other words, the current 
limited clinical ability to critically locate a potential conduction gap in a planned lesion, 
is an opportunity for both innovative tools and techniques aimed at improving such 
procedures.   
The primary objective of this report was to evaluate the relative clinical utility of 
simultaneously monitoring monophasic action potentials (MAPs) and contact forces as a 
means to improve one’s abilities to locate conduction gaps within elicited linear 
radiofrequency (RF) lesions. 
Methodology	  
These study protocols were reviewed and approved by the University of Minnesota 
Animal Care and Use Committee.  Two swine hearts were reanimated with a clear Krebs-
Henseleit buffer using Visible Heart® methodologies to generate video footage during 
ablation procedures: endocardial images were obtained using either a 4.0 or 6.0 mm 
diameter videoscope (Olympus, Center Valley, PA. .[149,150]   MAP signals were  
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characterize by determining relative occurrences and relative waveform properties 
relative to tip location of a catheter.  Thus, these signals enable a more detailed anatomic 
study of smaller areas of underlying myocardial substrate. [151,152,153,154]  MAP generation 
requires achieving a threshold of activation.  (Figure 7.1) 
 
Figure 7.1:  Shown is a depiction of the employed MAP catheter applied to the cardiac 
tissue: with a TAP moving past the type of the catheter with an amplitude of 30 mV.  The 
simultaneous deflections of the fiber Bragg grating provided the simultaneous force 
information.  TAP - transmembrane action potential, MAP – monophasic action potential 
A catheter was developed that allowed for both the ability to collect MAP signals and 
contact forces (CF) (grams): i.e., the forces were obtained utilizing an optical fiber bragg 
grating.  MAP signals were recorded as bipolar signals between tip electrodes to a 2 mm 
proximal ring electrode, using a filter bandwidth of 0.1 to 120 Hz for waveform collection.  
MAP collection was initiated with the presence of a signal morphology and a target  
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amplitude more than 2 mV.  CF was collected by placing a calibrated fiber bragg grating 
against the myocardium and capturing the change in frequency that occurs with physical 
deformation of the fiber bragg grating.  The calibration processes created the ability to 
derive the CF (grams).  Additionally, reference ECG signal collection was performed using 
a bipolar electrogram and was collected with a filter bandwidth of 0.1 to 120 Hz.  All MAP 
waveform collection and subsequent analyses was performed using the AD Instruments 
Bioamp system (Dunedin, New Zealand).  
The experimental approach employed here included endocardial and epicardial ablations 
that were comprised of given series of linear lesions created with a focal RF ablation 
catheter.  Direct visualization was used as a means to validate locations and catheter 
contacts.  Here we used the process of determining the presence of a conduction by 
collecting MAP signals pre-ablation and the required amounts of CFs on the given tissue 
location.  Any tissue that elicited a characteristic MAP was termed “conductive”.  Post-
ablations, all anatomic locations were reassessed to determine if  conduction gaps existed.  
In other words, if the amount of CF applied to a given location exceeded the pre-ablated CF 
and there was no detectable MAP signal, the location was deemed non-conductive.  
Furthermore, if MAP signals were present within a given ablated region, it was termed a gap 
in the linear lesion.  
The epicardial lesion patterns that was employed in the present study were fashioned 
after the work done by Ranjan and Kato et Al.  [146]  e.g., who devised a method for the 
creation and assessment of conduction gaps following applied linear lesions for epicardial  
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applications.  Specifically, here we generated lesions using a RF ablation system 
(Contactr catheter and an Atakr RF generator, Medtronic, Inc., Minneapolis, MN, USA).  
An initial power settings of 30 watts was used during the primary lesion pattern creation: 
note, additional applications of RF used (50 W over 10-30 seconds) were sometimes 
required for regions within the lesion pattern where MAPs persisted.   
To determine the conduction properties of the myocardium, electrical stimuli were delivered 
to the right ventricular (RV) epicardium using constant current with 2-millisecond (ms) 
pulse durations at twice diastolic thresholds, with a setting of 7-9 milliamps (mA).  (Figure 
7.2A) Direct visualization also aided to confirm that the catheter electrodes and force 
sensors were located at the same anatomical locations of the detectable lesions: i.e., to 
ensure accurate measurements were conducted.  (Figure 7.2A, B)  
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Figure 7.2:  Imaged of ablations performed on the reanimated swine heart specimens: 
(A) epicardial linear lesion on the RV with upper oval as external pacing site and lower 
oval contains tip of MAP catheter, and (B) LA endocardial image showing mitral isthmus 
linear lesion creation moving towards mitral valve annulus (green arrow).  LV – left 
ventricle, and MV mitral valve  RAA – right atrial appendage, RV – right ventricle. 
 
In addition to epicardial linear lesions, left atrial endocardial MI linear lesions were also 
created and examined for the presence of a given conduction gaps. CF collections in 
epicardial and endocardial locations were conducted at each measurement location, once 
4 consecutive MAP signals were observed.  This was done to compensate for the relative 
effects of cardiac movements and to prevent premature identifications of depolarization.  
Note, these effects were more prevalent for the epicardial assessments than for the 
endocardial ones.   
Multiple assessment locations were collected within each generated lesion set.  For 
example, the first pattern (set #1) shown in Figure 7.3A, contained a conduction gap at 
location B3.  After the creation of this epicardial H pattern, 6 CF measurements were 
obtained from 5 locations within the lesion pattern and 1 outside the pattern with MAP 
signals appearing at 2 (B3 and D1) locations (green) and a CF of 7.3 and 8.9 grams: note, 
both of these locations were non-ablated tissue (Figure 7.3B).   Further, no MAP signals 
were elicited within or recorded from the remaining 4 locations in this lesion pattern: A4, 
B2, C1, and C4 (red).  For these same epicardial studies, a second ablation of the pattern 
was then produced: this time, the only ablation related change was an additional 
application of RF in location B3.   
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Figure 7.3:  Elicited epicardial lesion patterns: (A) location of the linear lesion pattern on 
RV; (B) CF applied in different anatomic locations on or adjacent to the lesion pattern.  
CF is indicted for each location with red indicating no MAPs were detected and the green 
indicates that MAPs were elicited.  CF – contact force, MAP – monophasic action 
potential, RV right ventricle. 
 
MAP signal collections were attempted at locations A1, B2, B3, and C2 with no MAP 
detectable  at location B2 and B3 (red).  A further validation of the induced lesion pattern 
was also conducted by assessing for MAPs at locations A2, B2, C2.  A2 and C2: these 
locations were outside the lesion pattern and MAP signals were collected (green).  In this 
example, site B2 did not elicit a MAP signal with a CF of 8.9 grams (red).  The heart was 
then allowed to stabilize: lesion set 3 was then induced.  In this subsequent lesion set, 
only MAP and CF measurements were taken in the same locations as set #2 without any 
additional RF.  The applied CFs were stepwise increased in all locations to ensure good 
contact and the lack of any detectable MAP signals.  For example, at location B3 the 
reassessed CF was increased up to 11.1 grams and no MAP generated (red).  A2 and C2  
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were outside the lesion pattern and both generated MAPs with a peak force of 11.6 and 
12.0: at location B2 a peak CF of 11.1 grams was applied without the ability to record a 
MAP (red).  In summary, the use of this dual parameter assessment/mapping catheter was 
able to define the locations of the lesion gap in set #1.  Again, after an additional 
application of RF, at the gap, MAP signal detection was no longer possible.  Yet, catheter 
assessment validations were frequently conducted by measuring a location outside the 
lesion patterns and each time MAP signals were visible.  Finally, increased CF could be 
applied, so to ensure good tissue contacts.   
A similar approach was used in the creation of an endocardial left atrial MI ablation: 
linear RF lesion were generated.  In one example of this procedure, a MAP catheter was 
placed in 9 sequential locations on the generated linear lesion, in an attempt to record 
both MAPs and the CFs (Figure 7.4).  In this case, from locations 1, 4, 5, 6 it was not 
possible to record MAPs (red), but from the remaining locations it was (green).     
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Figure 7.4:  Provided here are the noted CFs for the placements of our assessment 
catheter at 9 anatomical locations on the endocardium of the LA in the region of the MI.  
Red bars indicates that no MAP was elicited and green indicates that a MAP recordings 
were obtained.  CFs in grams are listed for each of 9 locations on the lesion.  CF – 
contact force, LA – left atrium, MI – mitral isthmus. 
In this example, MAPs were recorded at CFs less than 10 grams.  Similar CFs were 
applied in the ablated anatomical locations where MAPs were not observed.  Too low of 
applied CFs and the presence of a MAP could be likely locations to additional RF 
application to increase the quality of the linear lesion.  These results which were 
reproducible in multiple isolated swine heart studies may provide novel approach to help 
one clinically identify the needs for additional ablations to minimize symptom 
recurrences.   
Conclusion	  
The creations of functional linear lesions either applied endocardially and epicardially 
relies on the effective applications of therapy.  Yet, often the resulting lesions can be 
varied in sizes and depths due to changes in tissue properties or changes in the amount of 
contact the given therapeutic catheter has with the underlying tissue.  Hence, the ability to 
use an adjuvant method that is able to detect the relative viability of the tissue at the 
location of the lesion at the time of the clinical application may allow for greater 
precision in creating a therapeutic linear lesion. Therefore, the use of a focal catheter that 
has means to simultaneously collect MAPs, contact forces, and create RF lesions may be 
a methodology to improve the overall clinical ablation procedure: i.e., by providing an 
innovative way to understand changes in a linear lesion at the time of their generation.  
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 Thesis	  Summary	  
The US Department of Health and Human Services reports that the treatment of atrial 
fibrillation (AF) using radiofrequency ablation is effective at stopping it in 74 out of 100 
patients when examined 1 year after the ablations were conducted. This outcome is in 
part influenced by limitations of current medical device system design and challenging 
anatomies.  Procedure outcomes and safety can be influenced by improving the 
understanding of how the anatomy interacts with these systems and examining innovative 
ways to use devices in the procedure.  This served as the background for my research 
with the following objective:   To improve the safety and therapeutic effectiveness of 
AF catheter ablation through translational research focused on cardiac anatomy, 
cardiac physiology, and medical device design.  
My research was organized into a series of studies beginning with an overview of the 
catheter ablation procedure for paroxysmal, persistent, and permanent AF.  This portion 
of the research focused on the impact of the therapeutic device and variations in cardiac 
anatomy to find opportunities for device improvement.  This overview contained insights 
that shaped the objectives of the subsequent studies.  The initial study undertaken was an 
examination of the interaction between the anatomy and mechanical properties of the 
fossa ovalis (FO) and the tools and techniques used in a transseptal puncture.  
Specifically, the puncture and tear forces of the FO were characterized when subjected to 
different forms of puncture and varying sized delivery systems to identity opportunities 
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for improved product/procedure safety and system usability.  Going beyond the 
transseptal puncture, additional studies focused on ways to improve ablation-related 
outcomes.  The initial therapeutic ablation lesion studied was the mitral isthmus (MI) 
linear ablation, used to terminate MI dependent left atrial flutter.  Summary of the clinical 
procedure and technologies and a study of the anatomy of the coronary sinus and MI 
were performed that shaped a recommendation for future improvements in devices and 
methods.  Next, a study of the generation of cardiac monophasic action potentials (MAP) 
were studied and correlated to contact force for both epicardial and endocardial anatomic 
locations.  This fundamental research characterized cardiac substrate activity at the point 
of catheter application providing insight into improvements in ablation therapies and 
improved specificity in identifying targeted tissues.  Lastly, a technical brief was used to 
introduce an innovative way to use MAPs and contact force as an adjuvant method in the 
creation of linear lesions.  These studies provide unique scientific contributions by 
describing anatomic changes in AF patients in the coronary sinus and MI anatomy and 
changes to the AF ablation clinical procedural technic to improve ablation therapy 
application and served as an input for catheter device design. Also for the first time, this 
research described the contact force needed to generate MAPs in a number of anatomic 
locations.  Finally, this research utilized an animal-based translational method to predict 
the behavior of transseptal tools in the human heart.  The anatomic limitations of the FO 
to withstand the forces associated with a transseptal puncture were analyzed with a 
recommendation made for improved device design related to puncture method and device  
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size.   
This catheter-based overview examined how ablation devices interface with tissue and  
how anatomic structures influence therapeutic success.  Since anatomy and physiology 
vary from person-to-person and the endocardial surface changes shape with each beat and 
can prompt catheter placement migration, it is difficult to know exactly where the device 
has been placed and what is happening at the device-tissue interface.  The unique ability 
of the Visible Heart apparatus to directly visualize the device tissue interface for each 
step in the procedure, allows an assessment of procedural limitations that contribute to 
the likelihood of arrhythmia reoccurrence and may increase AF ablation procedure time.  
The limitations identified in this unique model can serve as inputs into subsequent studies 
to improve patient safety and radio frequency (RF) ablation success.   
The aforementioned study of FO anatomic serves to improve knowledge by proposing a 
method that can translate to human clinical usage.  Limitations of current transseptal 
puncture tools and methods were discussed in addition to a study of how RF energy may 
be used as a way to improve the clinical procedure.  This experiment included the 
creation of a new method to determine puncture and tearing force of tissue and applied it 
through these novel translational in vitro studies, in both human and swine.  This work 
provides a perspective on the challenges of conducting a transseptal procedure and 
present compelling data for further discussion on device size constraints.  
In addition to the opportunities associated with the transseptal puncture, there also exist  
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opportunities to improve catheter navigation as it relates to movement, placement, 
orientation, and stability.  Ablation lesion formation is affected by catheter contact force 
and tissue thickness.  The vascular anatomy of the coronary sinus and the morphology of  
the MI, in the region of the left atrium (LA), may contribute to limiting the effectiveness 
of RF ablation aimed at generation of a transmural lesion. The comparison of CS 
anatomy between AF and non-AF anatomies relied on the reconstruction of magnetic 
resonance images (MRI) enabled a detailed assessment of the anatomic differences that 
affect catheter use.  This experiment used reconstructed AF anatomies to create unique 
insights such that greater contact force can be applied at the catheter tip to enable more 
precise tip placement in support of improved lesion generation.  This study considered 
ways to influence catheter design that would contribute to improving the efficacy of 
linear ablation of the MI.   
Understanding the interaction of devices with patient anatomy provides insights that can 
aid in therapeutic application.  Currently, the understanding of what is occurring at the 
specific site of lesion creation is limited by the clinically available imaging 
methodologies.  In this experiment, direct visualization of procedural technique was used 
to create unique visual insights as a method to report on ways to improving MI ablation 
outcomes.  Combining anatomic and procedural studies can improve the success of 
ablation.  However, if a gap in the linear lesion exists, additional information may be 
required to quantify the presence of discontinuity at the time of lesion formation.  
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MAPs offer the ability to describe the physiological properties as well as the viability of  
tissue that is present at the tip of the catheter. In this study of catheter use, we studied the 
relationship between MAP signal collection and contact force in a number of regional 
anatomies, both epicardially and endocardially.  The study of the dynamic relationship of  
the MAP in the presence of arrhythmias can provide unique insight into the underlying 
mechanisms that enable/sustain AF.  These innovative experiments created a way to 
simultaneously collect MAPs and contact force.  Through determination of the contact 
forces required to reliably generate MAP signals, catheter constructions and methods for 
manipulation can be developed to improve the reliability with which MAP signals can be 
generated.  These MAP signals can then be used as a way to determine if conduction gaps 
exist in linear lesion sets.  These novel insights should help both clinicians and catheter 
designers who have procedural requirements to generate reproducible MAPs from 
various locations in either the endocardium or on the epicardial surface.  The ability to 
accurately record these underlying myocardial potentials could provide critical 
information during ablation procedures or during attempts to focally deliver biologic 
therapies.   
Finally, the creation of linear lesions relies on the effective application of a focal catheter.  
The resulting lesion can vary in size and depth due to changes in tissue properties or 
changes in the amount of contact the catheter has with the tissue.  This research used the 
results of understanding MAP contact force and extended it to devise an adjuvant medical 
device method that is able to depict the viability of the tissue at the location of the lesion  
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at the time of lesion creation and shares these results in a technical brief.  The use of a 
focal catheter as a means to collect MAPs and create RF lesions may improve the overall 
clinical ablation procedure by providing evidence of conduction, or lack thereof, at the 
location of the lesion.  
This research primarily focused on challenges relating to the interaction of devices with 
the underlying cardiac anatomy.  The results suggest catheter design inputs to improve 
the procedure for patient safety and therapy effectiveness.   One important outcome of 
this work it that it has demonstrated that anatomy changes with the onset of AF and has 
exposed where limitations exist at the device-anatomy interface.  The research has also 
devised a way to translate tissue puncture from animal to human, derived the forces 
required to generate MAPs, and has made suggestions to improve the current clinical 
procedure including an introduction as to how to use contact force and MAPs  in linear 
lesion creation.   The implications of this research have the ability to impact how CS/MI 
anatomic changes affect catheter navigation, providing insight into how to achieve 
improved catheter positioning to increasing the effectiveness of ablations through better 
contact and retained position.  Understanding contact for MAPs will allow subsequent 
studies to bring together RF and MAP contact force to be used together to terminate 
conduction more effectively.  Finally, exposing the limits of the transseptal puncture and 
the limitations of the current technology suggest that new innovation is needed to find 
less traumatic and safer methods of conducting this step in the procedure.   
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